(A company incorporated with limited liability as an open-ended umbrella investment company with variable capital under the laws of Ireland)

## ANNUAL REPORT AND AUDITED FINANCIAL STATEMENTS

## FOR THE YEAR ENDED 31 DECEMBER 2014

Registration No. 489443

# SECTOR CAPITAL FUNDS PLC Annual Report and Audited Financial Statements For the year ended 31 December 2014

## TABLE OF CONTENTS

Page
General Information2
Directors' Report
Custodian's Report6
Investment Managers' Reports
Independent Auditors' Report
Balance Sheet
Profit and Loss Account
Statement of Changes in Net Assets attributable to holders of Redeemable Participating Shares
Schedules of Investments
Notes to the Financial Statements
Significant Portfolio Movements (Unaudited)

Annual Report and Audited Financial Statements For the year ended 31 December 2014

#### **GENERAL INFORMATION**

Directors

Michael Boyce (*Irish*)^ Peter Murray (*Irish*)^ Lars Tell (*Swedish*)

^Independent non-executive Director

**Investment Manager** 

Sector Global Equity Kernel Fund Sector Omega AS Filipstad Brygge 2 PO Box 1994 Vika N - 0125 Oslo Norway

**Investment Manager** 

Sector Healthcare Value Fund Sector Gamma AS Filipstad Brygge 2 PO Box 1994 Vika N - 0125 Oslo Norway

**Investment Manager** 

Sector Sigma Nordic Fund Sigma Fondsforvaltning AS Filipstad Brygge 2 PO Box 1994 Vika N - 0125 Oslo Norway

Administrator, Registrar and Transfer Agent

BNY Mellon Investment Servicing (International) Limited Riverside Two Sir John Rogerson's Quay Grand Canal Dock Dublin 2 Ireland

Custodian

BNY Mellon Trust Company (Ireland) Limited Guild House Guild Street IFSC Dublin 1 Ireland **Registered Office** 

2nd Floor, Beaux Lane House Mercer Street Lower Dublin 2 Ireland

**Independent Auditors** 

Deloitte & Touche Chartered Accountants and Statutory Audit Firm Deloitte & Touche House Earlsfort Terrace Dublin 2 Ireland

**Legal Advisers to the Company** (advisers as to Norwegian law) Bugge, Arentz-Hansen & Rasmussen Advokatfirma (BA-HR)

Tjuvholmen allé 16 NO-0252 Oslo PO Box 1524 Vika NO - 0117 Oslo Norway

Legal Advisers to the Company (advisers as to Irish law)

Maples and Calder 75 St. Stephen's Green Dublin 2 Ireland

**Sponsoring Brokers** 

Maples and Calder 75 St. Stephen's Green Dublin 2 Ireland

**Company Secretary** 

MFD Secretaries Limited 2nd Floor, Beaux Lane House Mercer Street Lower Dublin 2 Ireland

Annual Report and Audited Financial Statements For the year ended 31 December 2014

#### DIRECTORS' REPORT

The Directors present to the shareholders their annual report and the audited financial statements of Sector Capital Funds plc (the "Company") for the year 1 January 2014 to 31 December 2014.

#### **Principal Activities and Review of Business**

The Company was incorporated and registered in Ireland under the Companies Act, 1963 to 2013 as an open-ended umbrella investment company with variable capital and with segregated liability between sub-funds on 27 September 2010 with registered number 489443. The net assets of the Company were USD112,560,837 on 31 December 2014 (2013: USD 110,944,950).

The Company was authorised by the Central Bank of Ireland pursuant to European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations, 2011 (the "UCITS Regulations").

As at 31 December 2014, the Company has three funds in existence (31 December 2013: two), Sector Healthcare Value Fund, Sector Sigma Nordic Fund and Sector Global Equity Kernel Fund (the "Funds").

Sector Healthcare Value Fund commenced trading on 17 November 2010. The base currency of Sector Healthcare Value Fund is U.S. Dollars ("USD"). As at 31 December 2014 five classes are subscribed to in the Fund (31 December 2013: five), Class A EUR Shares, Class A NOK Shares, Class A USD Shares, Class B NOK Shares and Class L NOK Shares. Class A USD, Class A EUR and Class A NOK Shares were listed on the Irish Stock Exchange on 18 November 2010 and Class B NOK Shares were listed on the Irish Stock Exchange on 10 September 2013.

Sector Sigma Nordic Fund commenced trading on 25 June 2012. The base currency of the Fund is Norwegian Krone ("NOK"). As at 31 December 2014 seven classes are subscribed to in the Fund (31 December 2013: six), Class A EUR Shares, Class A NOK Shares, Class A USD, Class B EUR Shares, Class B NOK Shares, Class C NOK Shares and Class L NOK Shares. No application has been made to list the Shares on any stock exchange.

Sector Global Equity Kernel Fund commenced trading on 19 March 2014. The base currency of Sector Global Equity Kernel Fund is USD. As at 31 December 2014 three classes are subscribed to in the Fund, Class L NOK Shares, Class O NOK Shares and Class P USD Shares. Class P USD Shares were listed on the Irish Stock Exchange on 27 March 2014.

#### Results, Activities and Future Developments

The results of operations are set out on page 13. A detailed review of the business and future developments for the Funds is contained in the Investment Managers' Reports on page 7.

#### Statement of Directors' Responsibilities

Irish company law requires the Directors to prepare financial statements for each financial period which give a true and fair view of the state of affairs of the Company and of the profit or loss of the Company for that period. In preparing those financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and estimates that are reasonable and prudent; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business.

The Directors are responsible for keeping proper books of account which disclose with reasonable accuracy at any time the financial position of the Company and to enable them to ensure that the financial statements are prepared in accordance with accounting standards generally accepted in Ireland and comply with Irish statute comprising the Companies Acts, 1963 to 2013, the UCITS Regulations and the Listing Rules of the Irish Stock Exchange. They are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

#### **Accounting Records**

The Directors believe that they have complied with the requirements of section 202 of the Companies Act 1990 with regard to the books of account by employing the resources of an administrator, BNY Mellon Investment Servicing (International) Limited. During the year the books of the Company were maintained at the offices of the Administrator: BNY Mellon Investment Servicing (International) Limited, Riverside Two, Sir John Rogerson's Quay, Grand Canal Dock, Dublin 2.

#### Fair Value Directive

It is the opinion of the Board of Directors that the information required by the European Communities (Fair Value Accounting) Regulations 2004, in relation to the use by the Company of financial instruments and the financial risk management objectives and policies of the Company and the exposures of the Company to market risk, currency risk, interest rate risk, liquidity risk and credit risk is contained in the Investment Managers' Reports and note 7.

Annual Report and Audited Financial Statements For the year ended 31 December 2014

#### **DIRECTORS' REPORT (Continued)**

#### Significant events during the year

Sector Global Equity Kernel Fund commenced trading on 19 March 2014.

There were no other significant events during the year.

#### Significant events after the balance sheet date

A revised Supplement for Sector Sigma Nordic Fund was issued on 20 March 2015 to include Class D Shares.

There were no other significant events after the balance sheet date.

#### **Directors**

The current Directors are listed on page 2 and they served for the entire year.

#### **Directors' and Secretary's Interests**

The Directors and Secretary and their families had no interest in the shares of the Company at 31 December 2014, other than as disclosed in note 15 to the financial statements.

#### Dividends

Under the Articles of Association (the "Articles"), dividends may be paid out of the profits. During the year ended 31 December 2014, no dividends were paid.

#### **Corporate Governance Statement**

The Company is subject to and complies with the UCITS Regulations and the Listing Rules of the Irish Stock Exchange, as applicable to investment funds.

The Board has adopted the voluntary Irish Funds Industry Association (IFIA) Corporate Governance Code for Irish domiciled Collective Investment Schemes and Management Companies, issued 14 December 2011 (the "Code") with effect from 11 December 2012. The Board has reviewed and assessed the measures included in the Code and considers its corporate governance practices and procedures since the adoption of the Code as consistent therewith.

The Company is subject to corporate governance practices imposed by:

- 1. The Irish Companies Acts 1963 to 2013 and the UCITS Regulations which are available for inspection at the registered office of the Company and may also be obtained at www.irishstatutebook.ie.
- 2. The Articles of Association of the Company which are available for inspection at the registered office of the Company and at the Companies Registration Office in Ireland.
- 3. The Central Bank of Ireland in their UCITS Notices and Guidance Notes which can be obtained from the Central Bank of Ireland's website at: www.centralbank.ie and are available for inspection at the registered office of the Company.
- 4. The Irish Stock Exchange ("ISE") through the ISE Code of Listing Requirements and Procedures which can be obtained from the ISE's website at www.ise.ie.

Financial Reporting Process - description of main features

The Board is ultimately responsible for overseeing the establishment and maintenance of adequate internal control and risk management systems of the Company in relation to the financial reporting process. As the Company has no employees and two of the Directors serve in a non-executive capacity, all functions including the preparation of the financial statements have been outsourced. The Company has appointed BNY Mellon Investment Servicing (International) Limited, as its Administrator consistent with the regulatory framework applicable to investment fund companies such as the Company.

On appointing the Administrator, the Board noted that it was regulated by the Central Bank of Ireland and, in the Board's opinion, had significant experience as an administrator. The Board also noted the independence of the Administrator from the Company's Investment Managers. Subject to the supervision of the Board, the appointment of the Administrator is intended to manage rather than eliminate the risk of failure to achieve the Company's financial reporting objectives and can only provide reasonable and not absolute assurance against material misstatement or loss.

The annual and interim financial statements of the Company are required to be approved by the Board of the Company and filed with the Central Bank of Ireland and the Irish Stock Exchange. The statutory financial statements are required to be audited by independent auditors who report annually to the Board on their findings. The Board evaluates and discusses significant accounting and reporting issues as the need arises.

Annual Report and Audited Financial Statements For the year ended 31 December 2014

#### **DIRECTORS' REPORT (Continued)**

#### Corporate Governance Statement (continued)

Risk Assessment

The Board is responsible for assessing the risk of irregularities whether caused by fraud or error in financial reporting and for ensuring that processes are in place for the timely identification of internal and external matters with a potential effect on financial reporting. The Board's appointment of an administrator independent of the investment manager to the Company and which is regulated by Central Bank of Ireland is intended to mitigate though not eliminate the risk of fraud or irregularities which may impact the financial statements of the Company.

#### Monitoring

The Board receives regular presentations and reviews reports from the Custodian, Investment Manager and Administrator. The Board also has an annual process to ensure that appropriate measures are taken to consider and address any control weaknesses identified and measures recommended by the independent auditors.

#### Capital structure

No person has a significant direct or indirect holding of securities in the Company. No person has any special rights of control over the Company's share capital. There are no restrictions on voting rights.

For the appointment and replacement of Directors, the Company is governed by its Articles of Association, Irish Statute comprising the Companies Acts, 1963 to 2013, the UCITS Regulations, and the Listing Rules of the Irish Stock Exchange as applicable to investment funds. The Articles of Association themselves may be amended by special resolution of the shareholders.

Composition and operation of the board of directors

There are three Directors currently, two of whom are non-executive and are independent of the Investment Manager as required by the Irish Stock Exchange Listing Rules for investment funds. None of the Directors have entered into an employment or service contract with the Company. All related party transactions during the year are detailed in note 15 to the financial statements. The Articles of Association do not provide for retirement of Directors by rotation. However, the Directors may be removed by the shareholders by ordinary resolution in accordance with the procedures established under the Irish Companies Acts 1963 to 2013. The Board meets at least quarterly. There are no sub-committees of the Board.

The Board is responsible for managing the business affairs of the Company in accordance with the Articles of Association. Subject to its supervision and direction, the Board has delegated the day to day administration of the Company to the Administrator and the investment management and distribution functions to Sector Omega AS, Sector Gamma AS and Sigma Fondforvaltning AS as the Investment Managers. The Company has appointed BNY Mellon Trust Company (Ireland) Limited as the Custodian to the Company with responsibility for the safekeeping of the assets of the Company.

#### Shareholder meetings

The convening and conduct of shareholders' meetings are governed by the Articles of Association of the Company and the Companies Acts. Although the Directors may convene an extraordinary general meeting of the Company at any time, the Directors are required to convene an annual general meeting of the Company within fifteen months of the date of the previous annual general meeting. Shareholders representing not less than 10 percent of the paid up share capital of the Company may also request the Directors to convene a shareholders' meeting. Not less than twenty one days' notice of every annual general meeting and any meeting convened for the passing of a special resolution must be given to shareholders and fourteen days' notice must be given in the case of any other general meeting unless the auditors of the Company and all the shareholders of the Company entitled to attend and vote agree to shorter notice.

On a show of hands every shareholder who is present in person or by proxy shall have one vote. On a poll every shareholder present in person or by representative or proxy shall have one vote for every share for which is registered in the name of the shareholder. Such voting rights may be amended in the same manner as any other provision of the Trust Deed.

Shareholders may resolve to sanction an ordinary resolution or special resolution at a shareholders' meeting. An ordinary resolution of the Company requires a simple majority of the votes cast by the shareholders voting in person or by proxy at the meeting at which the resolution is proposed. A special resolution of the Company requires a majority of not less than 75% of the shareholders present in person or by proxy and voting in general meeting in order to pass a special resolution including a resolution to amend the Articles of Association.

#### Independent Auditors

Deloitte and Touche, Chartered Accountants and Statutory Audit Firm, have expressed their willingness to continue in office in accordance with Section 160(2) of the Companies Act, 1963.

On behalf of the Board of Directors

Date: 16 April 2015

Director



Dublin 2, Ireland

## Report of the Custodian to the Shareholders

We have enquired into the conduct of Sector Capital Funds plc (the "Company") for the year ended 31 December 2014, in our capacity as custodian to the Company.

This report including the opinion has been prepared for and solely for the shareholders in the Company, in accordance with the Central Bank of Ireland's UCITS Notice 4, and for no other purpose. We do not, in giving this opinion, accept or assume responsibility for any other purpose or to any other person to whom this report is shown.

#### Responsibilities of the Custodian

Our duties and responsibilities are outlined in the Central Bank of Ireland's UCITS Notice 4. One of those duties is to enquire into the conduct of the Company in each annual accounting period and report thereon to the shareholders.

Our report shall state whether, in our opinion, the Company has been managed in that period in accordance with the provisions of the Company's Memorandum and Articles of Association and the European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations 2011 (the "Regulations"). It is the overall responsibility of the Company to comply with these provisions. If the Company has not so complied, we as custodian must state why this is the case and outline the steps which we have taken to rectify the situation.

## **Basis of Custodian Opinion**

The custodian conducts such reviews as it, in its reasonable opinion, considers necessary in order to comply with its duties as outlined in UCITS Notice 4 and to ensure that, in all material respects, the Company has been managed (i) in accordance with the limitations imposed on its investment and borrowing powers by the provisions of its constitutional documentation and the appropriate regulations and (ii) otherwise in accordance with the Company's constitutional documentation and the appropriate regulations.

## **Opinion**


In our opinion, the Company has been managed during the year, in all material respects:

- (i) in accordance with the limitations imposed on the investment and borrowing powers of the Company by the Memorandum and Articles of Association and by the Regulations; and
- (ii) otherwise in accordance with the provisions of the Memorandum and Articles of Association and the Regulations.

BNY Mellon Trust Company (Ireland) Limited

Date: 16 April 2015

Nature Wel



Annual Report and Audited Financial Statements For the year ended 31 December 2014

#### **INVESTMENT MANAGERS' REPORTS**

#### **Sector Global Equity Kernel Fund**

Sector Global Equity Kernel Fund was launched on the 19th March 2014. The Fund is a Global equity long only fund, using the MSCI ACWI as its benchmark index.

The idea behind Sector Global Equity Kernel is to combine equity market returns with the harvest of risk premiums and alpha generation. The Investment Manager seeks to harvest the size, value and momentum risk premiums by investing in good companies at an attractive price, but only when they are trading in a positive trend. Because the Fund equal-weights positions, it tends to be short the size factor (the Fund's weighted average market—cap is lower than in the capital-weighted index). There are three generic sources of alpha in the Fund; bets on sectors, countries and stocks. Stock selection alpha is a result of how quality is assesses, value and momentum, how they are combined, as well as the Investment Manager's judgment. The Fund also strives to generate alpha from market and sector selection. Because the Fund is benchmark agnostic, countries or sectors are not over/underweight relative to benchmark weights. Rather, stocks are only bought from the sectors and countries where the Investment Manager adjudges that the "tide is rising".

During the nine months the Fund has been running, the portfolio was up 5% and outperforming the MSCI ACWI by 0.5%. On a single stock basis, the largest contributors to performance were Omnivision Technologies, Health Net and Kroger.

#### **Sector Healthcare Value Fund**

In 2014, the Healthcare sector ended up 18.1% versus 5.5% for the broader market making this the fourth consecutive year of outperformance both on a relative and absolute basis. The stand out sub sector was once again biotech, which ended up nearly 48% in 2014.

2014 certainly was an eventful year as many of our core themes continued to play out including maturing pipelines, a healthy pricing environment, increasing benefits from the Affordable Care Act (ACA) and the unstoppable M&A train. The changing political landscape in the US also plagued the sector in 2014, as the Republicans gained greater control of Congress following the mid-term elections and further legal challenges being lodged against elements of the ACA. Taxation was also high on the political agenda, with companies utilising inversions as part of their M&A strategy being labelled as "tax deserters" by the President. The result has been that some of the larger high profile deals were altered, where the inversion element was either removed or abandoned altogether. Although tax reform is a long and difficult path to follow, rhetoric is not. And the threat of not being able to "do business" with the government can be a powerful tool, especially in healthcare where 60 percent plus of revenues are directly or indirectly related to government budgets.

Sector Healthcare Value Fund was up 19.5% in 2014, outperforming the MSCI Healthcare Index by 1.4%. The largest contributors to performance were Edwards Lifesciences, Eli Lilly Lilly and Forest Labs. The largest detractors from performance were H Lundbeck, Sanofi and Daiichi.

#### Sector Sigma Nordic Fund

Global economic growth slowed further at the end of 2014, with the J.P. Morgan Global All-Industry Output Index registering a 14-month low while dropping to 52.3 in December. In our view, there is little to suggest that global growth momentum will pick up in the near-term. In fact, it appears that equity markets will continue to be challenged by tepid aggregate earnings growth in the coming quarters. We remain convinced that offshore-related oil exploration and production activity faces a multi-year downturn.

Sector Sigma Nordic Fund had a strong year and ended up 16.3% for 2014. In comparison, MSCI Nordic was up 13.2% and the Absolute UCITS European Equity Index was up 2.4% for the year. The Fund had positive contribution both from the long and short book. On a single stock basis, the Fund's largest performance contributors were Marine Harvest, Norsk Hydro and Royal Unibrew.

**Deloitte** 

Deloitte & Touche Chartered Accountants & Registered Auditors

## INDEPENDENT AUDITOR'S REPORT TO THE SHAREHOLDERS OF SECTOR CAPITAL FUNDS PLC

We have audited the financial statements of Sector Capital Funds Plc (the "Company") for the year ended 31 December 2014 which comprise the Balance Sheet, the Profit and Loss Account, the Statement of Changes in Net Assets attributable to holders of Redeemable Participating Shares, and the related notes 1 to 22. The financial reporting framework that has been applied in their preparation is Irish law and accounting standards issued by the Financial Reporting Council and promulgated by the Institute of Chartered Accountants in Ireland (Generally Accepted Accounting Practice in Ireland).

This report is made solely to the Company's shareholders, as a body, in accordance with Section 193 of the Companies Act, 1990. Our audit work has been undertaken so that we might state to the Company's shareholders those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Company and the Company's shareholders as a body, for our audit work, for this report, or for the opinions we have formed.

#### Respective responsibilities of directors and auditors

As explained more fully in the Statement of Directors Responsibilities, the directors are responsible for the preparation of the financial statements giving a true and fair view. Our responsibility is to audit and express an opinion on the financial statements in accordance with Irish law and International Standards on Auditing (UK and Ireland). Those standards require us to comply with the Auditing Practices Board's Ethical Standards for Auditors.

## Scope of the audit of the financial statements

An audit involves obtaining evidence about the amounts and disclosures in the financial statements sufficient to give reasonable assurance that the financial statements are free from material misstatement, whether caused by fraud or error. This includes an assessment of: whether the accounting policies are appropriate to the Fund's circumstances and have been consistently applied and adequately disclosed; the reasonableness of significant accounting estimates made by the directors; and the overall presentation of the financial statements. In addition, we read all the financial and non-financial information in the Annual Report and Audited Financial Statements to identify material inconsistencies with the audited financial statements and to identify any information that is apparently materially incorrect based on, or materially inconsistent with, the knowledge acquired by us in the course of performing the audit. If we become aware of any apparent material misstatements or inconsistencies we consider the implications for our report.

#### **Opinion**

In our opinion the financial statements:

- give a true and fair view, in accordance with Generally Accepted Accounting Practice in Ireland of the state of the affairs of the Company as at 31 December 2014 and of the Profit for the year then ended; and
- have been properly prepared in accordance with the Companies Acts, 1963 to 2013, and the European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations, 2011.

Continued on next page/



/Continued from previous page

## INDEPENDENT AUDITOR'S REPORT TO THE SHAREHOLDERS OF SECTOR CAPITAL FUNDS PLC

## Matters on which we are required to report by the Companies Acts 1963 to 2013

- We have obtained all the information and explanations we considered necessary for the purpose of our audit.
- In our opinion proper books of account have been kept by the Company.
- The Company's Balance Sheet and its Profit and Loss Account are in agreement with the books of account.
- In our opinion the information given in the Directors' Report is consistent with the financial statements.

## Matters on which we are required to report by exception

We have nothing to report in respect of the provisions in the Companies Acts 1963 to 2013 which requires us to report to you if, in our opinion the disclosures of directors' remuneration and transactions specified by law are not made.

Brian Forrester

For and on behalf of Deloitte & Touche Chartered Accountants and Statutory Audit Firm

Date:

16/4/2015

Annual Report and Audited Financial Statements For the year ended 31 December 2014

#### **BALANCE SHEET**

As at 31 December 2014

	Note	Sector Global Equity Kernel Fund USD	Sector Healthcare Value Fund USD	Sector Sigma Nordic Fund NOK	Sector Capital Funds PLC USD
Current Assets		4.	. 1		
Investments in financial assets held at fair value through profit or loss		9,881,148	57,796,560	. 213,541,976	96,164,207
Cash at bank and brokers	6	312,889	4,040,923	121,267,741	20,530,929
Amounts due from broker			_	2,311,226	308,317
Interest receivable		Normal Normal	_	792	106
Dividends receivable		10,720	62,059	_	72,779
Other assets		37,556	25,305	380,260	113,588
Total Assets		10,242,313	61,924,847	337,501,995	117,189,926
Current Liabilities					
Investments in financial liabilities held at fair value through profit or loss	•	-	276,068	150,887	296,196
Amounts due to broker		_	2,003,368	, –	2,003,368
Payable to investment manager	9	15,849	61,526	300,851	117,509
Incentive fee	10	7,211	429,465	6,897,032	1,356,740
Administration fee	11	21,359	31,732	248,009	86,175
Directors' fees and expenses	12	548	3,761	14,317	6,219
Auditors' fee	13	11,500	11,505	75,000	33,010
Custodian fee	11	17,480	5,876	38,638	28,510
Legal fee		6,431	329	1,925	7,017
Interest payable		3	-	305	44
Equalisation credit payable		1,515		1,090,157	619,799
Other creditors		7,892	42,051	184,099	74,502
Total Liabilities (excluding net assets attributable to holders of Redeemable Participating Shares)		89,788	3,338,538	9,001,220	4,629,089
Net assets attributable to holders of Redeemable Participating Shares		10,152,525	58,586,309	328,500,775	112,560,837
			1		
Shares outstanding	8				
Class A EUR		`. · <u>-</u>	97,848	47,121	
Class A NOK		,	15,692	74,103	
Class A USD		. –	85,070	1,355	
Class B EUR		, <u> </u>	-	10,416	
Class B NOK		-	96,094	88,301	
Class C NOK		·		2,498	
Class L NOK		4,000	25,492	20,184	
Class O NOK		1,623	_		•
Class P USD		90,075	-	-	
Net Asset Value per Share					
Class A EUR			169.75	110.34	
Class A NOK		ALIAN .	1,454.91	1,452.59	
Class A USD		_	233.38	111.61	
Class B EUR		_	000.06	135,20	
Class B NOK		-	802.06	1,407.23	
Class B USD		-	_	1 257 7F	
Class C NOK		1.004:45		1,377.75	
Class L NOK		1,004.45 728.02	1,561.53	1,589.47	
Class O NOK		728.02 105.01		Nove	
Class P USD		103.01	-	_	

Sector Global Equity Kernel Fund commenced operations on 19 March 2014.
Sector Sigma Nordic Fund is translated in the Company total column at the Balance Sheet exchange rate of 0.1334.

On behalf of the Board of Directors:

Director

Date: 16 April 2015

Director

Annual Report and Audited Financial Statements For the year ended 31 December 2014

## **BALANCE SHEET (Continued)**

As at 31 December 2013

	Note	Sector Healthcare Value Fund USD	Sector Sigma Nordic Fund NOK	Sector Capital Funds PLC USD
Current Assets		0.52	11011	652
Investments in financial assets held at fair value through profit or loss		75,956,578	180,159,433	105,646,852
Cash at bank and brokers	6	3,327,064	29,621,191	8,208,636
Amounts due from broker		473,300	_	473,300
Interest receivable		=	750	124
Dividends receivable		22,615	107,080	40,262
Other assets	_	46,359	533,962	134,356
Total Assets	_	79,825,916	210,422,416	114,503,530
Current Liabilities				
Investments in financial liabilities held at fair value through profit or loss		39,631	4,259,016	741,517
Amounts due to broker		132,463	231,909	170,682
Payable to investment manager	9	61,314	200,031	94,279
Incentive fee	10	629,942	3,181,818	1,154,306
Administration fee	11	31,096	198,428	63,797
Auditors' fee	13	11,149	87,507	25,570
Custodian fee	11	6,685	18,223	9,688
Legal fee		1,459	9,729	3,062
Equalisation credit payable		484,107	4,845,644	1,282,669
Other creditors		8,635	26,550	13,010
Total Liabilities (excluding net assets attributable to holders of Redeemable Participating Shares)	_	1,406,481	13,058,855	3,558,580
Net assets attributable to holders of Redeemable Participating Shares	_	78,419,435	197,363,561	110,944,950
Shares outstanding	8			
Class A EUR		98,930	=	
Class A NOK		15,692	42,745	
Class A USD		223,138	=	
Class B EUR		=	16,805	
Class B NOK		64,332	91,523	
Class B USD		_	6,454	
Class C NOK		_	2,071	
Class L NOK		25,492	5,936	
Net Asset Value per Share				
Class A EUR		141.84		
Class A NOK		1,200.84	1,248.89	
Class A USD		195.35		
Class B EUR		=	119.59	
Class B NOK		665.37	1,225.45	
Class B USD		=	120.19	
Class C NOK			1,204.57	
Class L NOK		1,269.13	1,317.87	

 $Sector\ Sigma\ Nordic\ Fund\ is\ translated\ in\ the\ Company\ total\ column\ at\ the\ Balance\ Sheet\ exchange\ rate\ of\ 0.1648.$ 

Annual Report and Audited Financial Statements For the year ended 31 December 2014

## **BALANCE SHEET (Continued)**

As at 31 December 2012

Total Net Asset Value	Sector Healthcare Value Fund USD 34,588,431	Sector Sigma Nordic Fund NOK 141,215,227
Shares outstanding	8	
Class A EUR	58,207	=-
Class A NOK	15,692	42,745
Class A USD	139,179	=
Class B EUR	_	90,711
Class B NOK	_	10
Class B USD	_	150
Class C NOK	_	-
Class L NOK	36,139	500
Net Asset Value per Share		
Class A EUR	99.58	-
Class A NOK	835.11	997.35
Class A USD	136.58	-
Class B EUR	_	98.44
Class B NOK	_	994.86
Class B USD	_	978.38
Class C NOK	_	_
Class L NOK	859.70	1,002.41

Annual Report and Audited Financial Statements For the year ended 31 December 2014

## PROFIT AND LOSS ACCOUNT

For the year ended 31 December 2014

	Note	Sector Global Equity Kernel Fund USD	Sector Healtheare Value Fund USD	Sector Sigma Nordic Fund NOK	Sector Capital Funds PLC USD
Income		041.500		4 517 525	2 271 052
Dividend income		241,569	1,310,743	4,517,535 606,329	2,271,052 96,482
Interest income		15	4,944	000,329	4,944
Other income		241,584	1,315,687	5,123,864	2,372,478
		241,304	1,515,007	3,123,001	2,5 / 2, 1 / 5
Net realised gain/(loss) on:					
- investments		(81,096)	21,237,881	33,844,535	26,541,450
- foreign currency		(265,801)	(4,503,880)	5,556,626	(3,885,622)
10101611 041101109					
Net change in unrealised appreciation/(depreciation) on:			V		
- investments		779,227	(3,684,185)	10,313,348	(1,264,104)
- foreign currency		(262,410)	(4,690,889)	5,377,131	(4,097,798)
Net investment gain		411,504	9,674,614	60,215,504	19,666,404
Net investment gain				···	
Expenses					
Management fee	9	(40,592)	(830,760)	(3,102,125)	(1,364,900)
Incentive fee	10	(23,405)	(215,765)	(7,221,787)	(1,388,156)
Administration fee	11	(59,003)	(143,547)	(1,183,316)	(390,816)
Custodian fee	11	(27,849)	(37,173)	(222,102)	(100,358)
Directors' fees and expenses	12	(1,460)	(16,667)	(52,939)	(26,550)
Auditors' fee		(11,500)	(12,128)	(57,022)	(32,700)
Commission fee		wheels	_	(26,860)	(4,273)
Dividend expense		· -	_	(3,093,859)	(492,233)
Legal fee		(9,999)	(20,395)	(190,287)	(60,669)
Listing fee		(2,140)	(4,522)	(9,313)	(8,144)
Trading and research fees			(66,865)	(400,407)	(130,570)
Other expenses		(19,330)	(78,882)	(337,375)	(151,888)
Total expenses before waivers		(195,278)	(1,426,704)	(15,897,392)	(4,151,257)
Expense waiver from Investment Manager	9	106,086			106,086
Net expenses after waivers		(89,192)	(1,426,704)	(15,897,392)	(4,045,171)
Net gain before finance costs		322,312	8,247,910	44,318,112	15,621,233
iver gain perore mance costs					
Finance costs					:
Interest expense		(309)	(2,903)	(318,336)	(53,859)
Total finance costs		(309)	(2,903)	(318,336)	(53,859)
T4		2.6			
Taxation Withholding tax		(53,362)	(311,804)	(1,078,159)	(536,701)
Net increase in net assets attributable to holders of Redeemable		(55,502)	(311,001)	(-)-1-3-27)	
Participating Shares resulting from operations		268,641	7,933,203	42,921,617	15,030,673
I at the patting shares resulting from operations		203,041	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		

There are no recognised gains or losses for the period other than those set out in the Profit and Loss Account. All activities relate to continuing operations.

Sector Global Equity Kernel Fund commenced operations on 19 March 2014.

Sector Sigma Nordic Fund is translated in the Company total column at the average exchange rate of 0.1591.

On behalf of the Board of Directors:

Date: 16 April 2015

Director

Annual Report and Audited Financial Statements For the year ended 31 December 2014

## **PROFIT AND LOSS ACCOUNT (Continued)**

For the year ended 31 December 2013

		Value Fund USD	Nordic Fund NOK	Sector Capital Funds PLC USD
Income				
Dividend income		819,492	3,090,885	1,345,251
Interest income	=	=	287,536	48,910
	-	819,492	3,378,421	1,394,161
Net realised gain/(loss) on:				
- investments		8,575,290	10,075,476	10,289,128
- foreign currency		75,752	5,436,805	1,000,553
Net change in unrealised appreciation/(depreciation) on:				
- investments		10,534,646	24,361,221	14,678,490
- foreign currency		97,061	6,513,763	1,205,052
Net investment gain	<del>-</del>	20,102,241	49,765,686	28,567,384
Expenses				
Management fee	9	(499,085)	(2,107,124)	(857,507)
Incentive fee	10	(668,497)	(3,256,112)	(1,222,362)
Administration fee	11	(113,793)	(878,008)	(263,142)
Custodian fee	11	(29,487)	(195,943)	(62,817)
Directors' fees and expenses	12	(17,588)	(54,015)	(26,776)
Auditors' fee		(10,815)	(87,281)	(25,661)
Dividend expense		(20.172)	(2,463,234)	(418,996)
Legal fee		(39,172)	(233,499)	(78,890)
Listing fee		(8,812)	(2,188)	(9,184)
Trading and research fees		(25,115)	(301,735)	(76,440)
Other expenses Total expenses before waivers	-	(55,161) (1,467,525)	(227,130) (9,806,269)	(93,796) (3,135,571)
Total expenses before warvers		(1,407,323)	(9,800,209)	(3,133,371)
Net gain before finance costs	<del>-</del>	18,634,716	39,959,417	25,431,813
Finance costs				
Interest expense	_	(414)	(145,837)	(25,221)
Total finance costs	=	(414)	(145,837)	(25,221)
Taxation				
Withholding tax	_	(179,090)	(798,747)	(314,957)
Net increase in net assets attributable to holders of Redeemable Participating Shares resulting from operations	: 	18,455,212	39,014,833	25,091,635

There are no recognised gains or losses for the period other than those set out in the Profit and Loss Account. All activities relate to continuing operations.

Sector Sigma Nordic Fund is translated in the Company total column at the average exchange rate of 0.1701.

Annual Report and Audited Financial Statements For the year ended 31 December 2014

## STATEMENT OF CHANGES IN NET ASSETS ATTRIBUTABLE TO HOLDERS OF REDEEMABLE PARTICIPATING SHARES

For the year ended 31 December 2014

	Sector Global Equity Kernel Fund USD	Sector Healthcare Value Fund USD	Sector Sigma Nordic Fund NOK	Sector Capital Funds PLC USD
Net Assets attributable to holders of Redeemable Participating				
Shares at beginning of year		78,419,435	197,363,561	110,944,950
Capital transactions:				
Issue of Redeemable Participating Shares	12,534,409	28,664,533	148,054,660	64,754,438
Redemption of Redeemable Participating Shares	(2,638,004)	(56,059,711)	(58,731,004)	(68,041,818)
Equalisation applied	(12,521)	(371,151)	(1,108,059)	(559,964)
Net increase/(decrease) in net assets resulting from capital				
transactions of Redeemable Participating Shares	9,883,884	(27,766,329)	88,215,597	(3,847,344)
Currency adjustment	-	_	-	(9,567,442)
Net increase in net assets attributable to holders of Redeemable				
Participating Shares resulting from operations	268,641	7,933,203	42,921,617	15,030,673
Net Assets attributable to holders of Redeemable Participating				
Shares at end of year	10,152,525	58,586,309	328,500,775	112,560,837

 $Sector\ Sigma\ Nordic\ Fund\ is\ translated\ in\ the\ total\ column\ at\ the\ average\ exchange\ rate\ of\ 0.1591.$ 

Annual Report and Audited Financial Statements For the year ended 31 December 2014

## STATEMENT OF CHANGES IN NET ASSETS ATTRIBUTABLE TO HOLDERS OF REDEEMABLE PARTICIPATING SHARES (Continued)

For the year ended 31 December 2013

	Sector Healthcare Value Fund USD	Sector Sigma Nordic Fund NOK	Sector Capital Funds PLC USD
Net Assets attributable to holders of Redeemable Participating			
Shares at beginning of year	34,588,431	141,215,227	59,964,807
Capital transactions:			
Issue of Redeemable Participating Shares	39,307,013	44,538,072	46,882,939
Redemption of Redeemable Participating Shares	(13,505,859)	(22,423,043)	(17,320,018)
Equalisation applied	(425,362)	(4,981,528)	(1,272,720)
Net increase in net assets resulting from capital transactions of			
Redeemable Participating Shares	25,375,792	17,133,501	28,290,201
Currency adjustment	-	_	(2,401,693)
Net increase in net assets attributable to holders of Redeemable			
Participating Shares resulting from operations	18,455,212	39,014,833	25,091,635
Net Assets attributable to holders of Redeemable Participating			
Shares at end of year	78,419,435	197,363,561	110,944,950

Sector Sigma Nordic Fund is translated in the total column at the average exchange rate of 0.1701.

**Annual Report and Audited Financial Statements** For the year ended 31 December 2014

## SCHEDULES OF INVESTMENTS

As at 31 December 2014

## **Sector Global Equity Kernel Fund**

Sector Global Equity Kernel Fund		Fair Value as a % of	
Investment	Units	Net Assets	Fair Value USD
Financial Assets at Fair Value through profit or loss			
Equities			
Australia			
M2 Telecommunications Group Ltd.	14,399	0.94%	95,799
Telstra Corp Ltd.	20,033	0.96%	97,872
Total Australia		1.90%	193,671
Canada	1.000	0.020/	02.504
Canadian Imperial Bank of Commerce Genworth MI Canada, Inc.	1,088 2,809	0.92% 0.88%	93,784 89,684
Magna International, Inc.	889	0.95%	96,625
Total Canada		2.75%	280,093
China			
China Mobile Ltd.	8,000	0.92%	93,361
Sino Biopharmaceutical Ltd.	88,000	0.79%	79,775
Total China		1.71%	173,136
Finland			
Elisa Oyj	3,639	0.98%	99,560
Total Finland		0.98%	99,560
France			
Ipsen S.A.	1,970	1.01%	102,503
Orange S.A.	6,051	1.02%	103,606
Societe BIC S.A. Total France	775	1.01%	103,016 309,125
		3.0470	309,123
Germany Freenet AG	3,640	1.03%	104,367
Henkel KGaA	1,050	1.03%	102,203
Total Germany		2.04%	206,570
Hong Kong			
Guangdong Investments Ltd.	70,000	0.90%	91,169
Total Hong Kong		0.90%	91,169
Japan			
Ain Pharmaciez, Inc.	3,700	1.05%	106,468
Asahi Kasei Corp.	12,000	1.09%	110,647
Bridgestone Corp. KDDI Corp.	2,700 1,600	0.93%	94,560 101,916
Lintec Corp.	4,800	1.00% 1.06%	107,254
Maeda Road Construction Co. Ltd.	7,000	1.03%	104,625
Mitsubishi Electric Corp.	8,000	0.95%	96,484
NTT DoCoMo, Inc.	6,300 25,000	0.91%	92,901 94,041
Osaka Gas Co. Ltd. Resona Holdings, Inc.	17,300	0.93% 0.87%	88,293
Tokyo Gas Co. Ltd.	18,000	0.96%	97,901
Total Japan		10.78%	1,095,090
Netherlands			
Koninklijke Ahold NV	5,446	0.96%	97,234
TKH Group NV	3,050	0.96%	97,286
Unilever NV Total Natharlanda	2,630	1.02%	103,875
Total Netherlands		2.94%	298,395
Singapore			40= 4
Flextronics International Ltd.	9,612	1.06%	107,462
Total Singapore		1.06%	107,462

Annual Report and Audited Financial Statements For the year ended 31 December 2014

## **SCHEDULES OF INVESTMENTS (continued)**

As at 31 December 2014

## **Sector Global Equity Kernel Fund (Continued)**

Primarcial Assets at Fair Value through profit or loss continued!	1	Fair		
Spain         3,534         0.88%         88,909           Total Spain         3,534         0.88%         88,909           Total Spain         80         1,10%         11,10%         11,0%         10,0	Investment	Units	Net Assets	Fair Value USD
Spain         3,534         0.88%         88,909           Total Spain         3,534         0.88%         88,909           Total Spain         80         1,10%         11,10%         11,0%         10,0	Financial Assets at Fair Value through profit or loss			
Gas Natural SDG S.A.         3,534         0.88%         88,900           Switzerland         BB Bitocch AG         469         1.10%         11,486           Partiners Group Holding AG         371         1.00%         18,781           Switzerland         167         0.86%         87,815           Total Switzerland         2500         0.95%         307,392           United Kingdom         8cretely Group Holdings PLC         2,500         0.95%         104,192           Echeley Group Holdings PLC         16,643         1.03%         104,192           Calbie & Wireless Communications PLC         16,643         1.03%         104,192           Calbie & Wireless Communications PLC         1,644         0.95%         96,673         104,192           Delphi Automotive PLC         4,480         0.95%         104,234         104,192         104				
Gas Natural SDG S.A.         3,534         0.88%         88,900           Switzerland         BB Bitocch AG         469         1.10%         11,486           Partiners Group Holding AG         371         1.00%         18,781           Switzerland         167         0.86%         87,815           Total Switzerland         2500         0.95%         307,392           United Kingdom         8cretely Group Holdings PLC         2,500         0.95%         104,192           Echeley Group Holdings PLC         16,643         1.03%         104,192           Calbie & Wireless Communications PLC         16,643         1.03%         104,192           Calbie & Wireless Communications PLC         1,644         0.95%         96,673         104,192           Delphi Automotive PLC         4,480         0.95%         104,234         104,192         104	Spain			
Switzerland		3,534	0.88%	88,990
Switzerland BB Biotech AG				
BB Biotech AG	•			
Parmers Group Holding AG   10,0%   87,815     Total Switzerland   10,0%   30,03%   307,392     United Kingdom		460	1.100/	111 406
Swisseom AG         167         0.86%         87.815           Total Switzerland         3.02%         307.392           United Kingdom         Berkeley Group Holdings PLC         2.500         0.95%         6.673           British Telecommunications PLC         126,643         1.03%         104,192           Cable & Wireless Communications PLC         129,500         0.99%         100,234           Clay Beld Wireless Communications PLC         1,370         0.08%         90,626           Hikma Pharmaceuticals PLC         1,370         0.08%         90,626           Hikma Pharmaceuticals PLC         10,139         1.12%         113,668           WFP PLC         950         0.07%         98,895           Total United Kingdom         9,14,777         10,118         102,603           WFP PLC         950         0.07%         98,895           Total United Kingdom         9,14,777         10,118         10,304           Atron's Inc.         3,805         1.15%         11,631           Aaron's Inc.         3,805         1.15%         116,319           Atronical Electric Power Co, Inc.         3,805         1.15%         116,319           Atronical Electric Power Co, Inc.         1,700         1.02				
Total Switzerland				
Berkeley Group Holdings PLC         2.500         0.95%         96.673           Briish Telecommunications PLC         16.643         1.03%         104.192           Cable & Wireless Communications PLC         129.500         0.99%         100.234           Cranswick PLC         4.480         0.95%         96.6748           Delphi Automotive PLC         1.370         0.98%         99.626           Hikm Pharmaceuticals PLC         10.139         1.12%         112.630           IG Group Holdings PLC         4.170         1.01%         102.603           WPP PLC         4.970         0.97%         98.895           Total United Kingdom	Total Switzerland			
Berkeley Group Holdings PLC         2.500         0.95%         96.673           Briish Telecommunications PLC         16.643         1.03%         104.192           Cable & Wireless Communications PLC         129.500         0.99%         100.234           Cranswick PLC         4.480         0.95%         96.6748           Delphi Automotive PLC         1.370         0.98%         99.626           Hikm Pharmaceuticals PLC         10.139         1.12%         112.630           IG Group Holdings PLC         4.170         1.01%         102.603           WPP PLC         4.970         0.97%         98.895           Total United Kingdom	W 5 177 1			
Britist Telecommunications PLC         16,643         1,03%         104,192           Cable & Wireless Communications PLC         129,500         0.99%         100,234           Canswick PLC         4,480         0.95%         96,748           Delphi Automotive PLC         1,370         0.98%         99,626           Hikma Pharmaceuticals PLC         10,139         1,12%         113,668           Group Holdings PLC         4,170         1,01%         102,608           WPP PLC         50         0,97%         98,858           Total United Kingdom         2018         1,15%         116,108            3,805         1,15%         116,319           Actina, Inc.         1,160         1,01%         103,043           American Electric Power Co, Inc.         1,700         1,02%         103,224           Annal Capital Management, Inc.         8,790         0,94%         95,020           Anthem, Inc.         2,91         0,99%         100,667           Archer-Daniels-Midland Co.         1,91         0,99%         99,766           Assis Capital Holdings Ltd.         2,01         0,99%         99,766           Assis Capital Holdings Ltd.         2,01         0,99%         99,		2 500	0.95%	96 673
Cable & Wireless Communications PLC         4,48         0.99%         100,234           Cranswick PLC         4,48         0.95%         96,748           Delphi Automotive PLC         1,370         0.98%         96,748           Hikma Pharmaceuticals PLC         10,139         1.12%         113,688           G Group Holdings PLC         4,170         1.01%         102,603           Persimnon PLC         4,170         1.01%         102,603           WPP PLC         95         0.97%         98,895           Total United Kingdom         8         0.97%         98,895           Total United Kingdom         8         0.90%         914,777           United States         8         1.15%         116,319           Actma, Inc.         1,160         1.01%         103,043           America Corp.         2,303         1.05%         106,224           American Electric Power Co, Inc.         1,700         1,02%         103,224           Ammican Electric Power Co, Inc.         1,700         1,02%         103,622           Ammerican Electric Power Co, Inc.         2,700         1,04%         103,043           American Electric Power Co, Inc.         1,700         1,02%         103,043 <td>, ,</td> <td>,</td> <td></td> <td></td>	, ,	,		
Cramswick PLC         4,480         0.95%         96,748           Delphi Autmotive PLC         1,370         0.98%         99,626           Hikma Pharmaceuticals PLC         10,139         1,12%         113,668           Persimnon PLC         4,170         1,01%         102,668           WPP PLC         50         0,97%         98,885           Total United Kingdom         20         0,91%         91,477           Linited States         3,805         1,15%         116,319           Actma, Inc.         1,160         1,01%         103,043           American Electric Power Co, Inc.         1,700         1,02%         103,224           Annialy Capital Management, Inc.         8,790         0,94%         95,020           Anthem, Inc.         725         0,99%         9,111           Apple Computer, Inc.         912         0,99%         9,116           Archer-Daniels-Midland Co.         1,908         0,98%         99,216           Asspen Insurance Holdings Ltd.         2,20         0,98%         99,216           Asspen Insurance Holdings Ltd.         2,20         0,98%         99,796           Axis Capital Holdings Ltd.         2,00         1,00%         10,10%         10,269<				
Himm Pharmaceuticals PLC	Cranswick PLC	4,480	0.95%	
Group Holdings PLC         10,139         11,2%         113,66,80           Persimmon PLC         4,170         1,01%         102,680           WPP PLC         9,91%         98,895           Total United Kingdom				
Persiminon PLC         4,170         1.01%         102.603           WPP PLC         950         0.97%         98,805           Total United Kingdom         2         9.01%         914.777           United States         3,805         1.15%         116.189           Actma, Inc.         1,160         1.01%         103.043           American Electric Power Co, Inc.         1,700         1.05%         105,237           American Electric Power Co, Inc.         1,700         1.04%         95,020           Annaly Capital Management, Inc.         2,725         0.90%         91,111           Apple Computer, Inc.         912         0.99%         190,066           Archer-Daniels-Midland Co.         1,908         0.98%         99,216           Aspen Insurance Holdings Ltd.         2,210         0.98%         99,216           Aspen Insurance Holdings Ltd.         2,010         1.01%         102,691           Benchmark Electronics, Inc.         4,111         1.03%         104,84           Broadcom Corp.         2,400         1.02%         103,92           Broadcom Corp.         2,400         1.00%         101,720           Cardinal Health, Inc.         2,230         0.86%         87,037				
WP PLC         950         0.97%         98.895           Total United Kingdom         9.01%         914.777           United States         3.805         1.15%         116.319           Aeron's Inc.         1.160         1.01%         103.043           Aemen Corp.         2.303         1.05%         106.237           American Electric Power Co, Inc.         1.700         1.02%         103.224           Annaly Capital Management, Inc.         8.790         0.94%         95.020           Anthern, Inc.         725         0.99%         100.667           Archer-Damiels-Midland Co.         1.908         0.99%         99.216           Aspen Insurance Holdings Ltd.         2,280         0.99%         99.796           Asis Capital Holdings Ltd.         2,010         1.01%         102.691           Benchmark Electronics, Inc.         4,111         1.03%         104.584           BlackRock, Inc.         262         0.92%         93.681           Broadcom Corp.         2,400         1.02%         103.992           Bunge Ltd.         1,120         1.00%         101.819           Cardinal Health, Inc.         2,230         8.6%         87.037           Cardinal Health, Inc. <td></td> <td></td> <td></td> <td></td>				
Dutied States				
Dirict States				
Aaron's Inc.         3,805         1,15%         116,319           Aetna, Inc.         1,160         1,01%         103,043           Ameren Corp.         2,303         1,05%         106,237           American Electric Power Co, Inc.         1,700         1,02%         103,224           Annaly Capital Management, Inc.         8,790         0,94%         95,020           Anthem, Inc.         725         0,90%         91,111           Apple Computer, Inc.         1912         0,99%         100,667           Archer-Daniels-Midland Co.         1,908         0,98%         99,216           Aspen Insurance Holdings Ltd.         2,280         0,98%         99,976           Axis Capital Holdings Ltd.         2,280         0,98%         99,976           Axis Capital Holdings Ltd.         2,200         0,92%         93,681           Broadcom Corp.         2,400         1,00%         101,819           Cal-Maine Foods, Inc.         1,260         1,00%         1				
Aetna, Inc.         1,160         1.01%         103,043           American Corp.         2,303         1.05%         105,224           American Electric Power Co, Inc.         1,700         1.02%         103,224           Annaly Capital Management, Inc.         8,790         0.94%         95,020           Anthem, Inc.         725         0.90%         91,111           Apple Computer, Inc.         912         0.99%         100,667           Archer-Daniels-Midland Co.         1,908         0.98%         99,216           Aspen Insurance Holdings Ltd.         2,280         0.98%         99,216           Axis Capital Holdings Ltd.         2,010         1.01%         102,691           Benchmark Electronics, Inc.         4,111         1.03%         104,584           BlackRock, Inc.         262         0.92%         93,681           Broadcom Corp.         2,400         1.02%         103,992           Bunge Ltd.         1,120         1.00%         101,819           Carlwalinia Foods, Inc.         2,230         0.86%         87,037           Carlwalinia, Inc.         1,260         1.00%         101,720           Century Link, Inc.         2,50         0.98%         99,742      <		2.005	1 150/	116 210
Ameren Corp.         2,303         1.05%         106,237           American Electric Power Co, Inc.         1,700         1.02%         103,224           Annaly Capital Management, Inc.         8,790         0,94%         95,020           Annaly Capital Management, Inc.         725         0,90%         91,111           Apple Computer, Inc.         1912         0,99%         100,667           Archer-Daniels-Midland Co.         1,908         0,98%         99,216           Aspen Insurance Holdings Ltd.         2,280         0,98%         99,216           Aspen Insurance Holdings Ltd.         2,010         1.01%         102,691           Benchmark Electronics, Inc.         4,111         1.03%         104,584           Black Rock, Inc.         262         0,92%         93,581           Broadcom Corp.         2,400         1.02%         103,992           Bunge Ltd.         1,120         1.00%         101,819           Cal-Maine Foods, Inc.         2,230         0.86%         87,037           Cal-Maine Foods, Inc.         1,260         1.00%         101,720           Cal-Maine Foods, Inc.         2,230         0.86%         87,037           Cal-Maine Foods, Inc.         1,20         0.09%				
American Electric Power Co, Inc.         1,700         1,02%         103,224           Annaly Capital Management, Inc.         8,790         0,94%         95,020           Anthem, Inc.         725         0,90%         91,111           Apple Computer, Inc.         1912         0,99%         100,667           Archer-Daniels-Midland Co.         1,908         0,98%         99,216           Aspen Insurance Holdings Ltd.         2,280         0,98%         99,796           Axis Capital Holdings Ltd.         2,010         1.01%         102,691           Benchmark Electronics, Inc.         4,111         1.03%         104,584           BlackRock, Inc.         262         0,92%         93,681           Broadcom Corp.         2,400         1,00%         101,819           Cal-Maine Foods, Inc.         2,230         0,86%         87,037           Cardinal Health, Inc.         1,260         1,00%         101,720           Century Link, Inc.         2,520         0,98%         99,742           Chimera Investment Corp.         1,560         1,01%         102,976           CVS Caremark Corp.         1,640         1,01%         102,976           CVS Caremark Corp.         1,640         1,01% <td< td=""><td></td><td></td><td></td><td></td></td<>				
Anthem, Inc.         725         0.90%         91,111           Apple Computer, Inc.         912         0.99%         100,667           Archer-Daniels-Midland Co.         1,908         0.98%         99,216           Aspen Insurance Holdings Ltd.         2,280         0.98%         99,796           Axis Capital Holdings Ltd.         2,010         1.01%         102,691           Benchmark Electronics, Inc.         4,111         1.03%         104,584           BlackRock, Inc.         262         0.92%         93,681           Broadcom Corp.         2,400         1.02%         103,992           Bunge Ltd.         1,120         1.00%         101,819           Cal-Maine Foods, Inc.         2,230         0.86%         87,037           Cardinal Health, Inc.         1,260         1.00%         101,720           Century Link, Inc.         2,520         0.98%         99,742           Chimera Investment Corp.         29,900         0.94%         95,082           Consolidated Edison, Inc.         1,560         1.01%         102,096           Corp.         1,640         1.01%         102,096           Eutres Ke Group Ltd.         580         0.97%         98,774           <				
Apple Computer, Inc.         912         0.99%         100,667           Archer-Daniels-Midland Co.         1,908         0.98%         99,216           Aspen Insurance Holdings Ltd.         2,280         0.98%         99,796           Axis Capital Holdings Ltd.         2,010         1,01%         102,691           Benchmark Electronics, Inc.         4,111         1,03%         104,584           BlackRock, Inc.         262         0.92%         36,818           Broadcom Corp.         2,400         1,02%         103,992           Bunge Ltd.         1,120         1,00%         101,819           Cal-Maine Foods, Inc.         2,230         0.86%         87,037           Carl Maine Foods, Inc.         2,250         0.98%         99,742           Century Link, Inc.         2,500         0.94%         95,082           Cardinal Health, Inc.         2,500         0.94%         95,082           Consolidated Edison, Inc.         1,560         1,01%         102,976           CVS Caremark Corp.         1,116         1,06%         107,482           Deluxe Corp.         1,560         1,01%         102,996           Everest Re Group Ltd.         58         0,97%         98,774 <t< td=""><td>Annaly Capital Management, Inc.</td><td>8,790</td><td>0.94%</td><td>95,020</td></t<>	Annaly Capital Management, Inc.	8,790	0.94%	95,020
Archer-Daniels-Midland Co.         1,908         0,98%         99,216           Aspen Insurance Holdings Ltd.         2,280         0,98%         99,796           Axis Capital Holdings Ltd.         2,010         1,01%         102,691           Benchmark Electronics, Inc.         4,111         1,03%         104,584           BlackRock, Inc.         262         0,92%         93,681           Broadcom Corp.         2,400         1,02%         103,992           Bunge Ltd.         1,120         1,00%         101,819           Cal-Maine Foods, Inc.         2,230         0,86%         87,037           Cardinal Health, Inc.         2,520         0,98%         99,742           CenturyLink, Inc.         2,520         0,98%         99,742           Chimera Investment Corp.         29,900         0,94%         95,082           Consolidated Edison, Inc.         1,560         1,01%         102,976           CVS Caremark Corp.         1,640         1,01%         102,906           Entergy Corp.         1,640         1,01%         102,906           Entergy Corp.         1,640         1,01%         107,906           Everest Re Group Ltd.         580         0,97%         98,774 <tr< td=""><td></td><td></td><td></td><td></td></tr<>				
Aspen Insurance Holdings Ltd.         2,280         0,98%         99,796           Axis Capital Holdings Ltd.         2,010         1.01%         102,691           Benchmark Electronics, Inc.         4,111         1.03%         104,584           BlackRock, Inc.         262         0,92%         93,681           Broadcom Corp.         2,400         1.02%         103,992           Bunge Ltd.         1,120         1.00%         101,819           Cal-Maine Foods, Inc.         2,230         0.86%         87,037           Cardinal Health, Inc.         1,260         1.00%         101,720           CenturyLink, Inc.         2,520         0.98%         99,742           Chimera Investment Corp.         29,900         0.94%         95,082           Consolidated Edison, Inc.         1,560         1.01%         102,976           CVS Caremark Corp.         1,116         1.06%         107,482           Deluxe Corp.         1,200         1.03%         104,976           Everest Re Group Ltd.         580         0.97%         98,774           Exverset Re Group Ltd.         580         0.97%         10,770           Everest Re Group Ltd.         580         0.97%         10,770				
Axis Capital Holdings Lid.         2,010         1.01%         102,691           Benchmark Electronics, Inc.         4,111         1.03%         104,584           BlackRock, Inc.         262         0.92%         93,681           Broadcom Corp.         2,400         1.02%         103,992           Bunge Ltd.         1,120         1.00%         101,819           Cal-Maine Foods, Inc.         2,230         0.86%         87,037           Cardinal Health, Inc.         1,260         1.00%         101,720           CenturyLink, Inc.         2,520         0.98%         99,742           Chimera Investment Corp.         29,900         0.94%         95,082           Consolidated Edison, Inc.         1,560         1.01%         102,976           CVS Caremark Corp.         1,116         1.06%         107,482           Deluxe Corp.         1,640         1.01%         102,090           Entergy Corp.         1,200         1.03%         104,976           Everest Re Group Ltd.         580         0.97%         98,774           Exory Stworks, Inc.         790         1,02%         103,067           General Electric Co.         3,740         0.93%         94,510           Gra				
Benchmark Electronics, Inc.         4,111         1.03%         104,584           BlackRock, Inc.         262         0,92%         93,681           Broadcom Corp.         2,400         1.02%         103,992           Bunge Ltd.         1,120         1.00%         101,819           Cal-Maine Foods, Inc.         2,230         0.86%         87,037           Cardinal Health, Inc.         2,520         0.98%         99,742           CenturyLink, Inc.         2,520         0.98%         99,742           Chimera Investment Corp.         29,900         0.94%         95,082           Consolidated Edison, Inc.         1,560         1.01%         102,976           CVS Caremark Corp.         1,640         1.01%         102,096           Ever Screat Re Group Ltd.         580         0.97%         98,774           Evxon Mobil Corp.         1,090         0.99%         100,770           Everest Re Group Ltd.         580         0.97%         98,774           Evxon Mobil Corp.         1,090         0.99%         100,770           F5 Networks, Inc.         790         1.02%         103,067           General Electric Co.         3,740         0.93%         94,510           G				
Broadcom Corp.         2,400         1.02%         103,992           Bunge Ltd.         1,120         1.00%         101,819           Cal-Maine Foods, Inc.         2,230         0.86%         87,037           Cardinal Health, Inc.         1,260         1.00%         101,720           CenturyLink, Inc.         2,520         0.98%         99,742           Chimera Investment Corp.         29,900         0.94%         95,082           Consolidated Edison, Inc.         1,560         1.01%         102,976           CVS Caremark Corp.         1,116         1.06%         107,482           Deluxe Corp.         1,640         1.01%         102,090           Entergy Corp.         1,640         1.01%         102,090           Everest Re Group Ltd.         580         0.97%         98,774           Exxon Mobil Corp.         1,090         0.99%         100,770           F5 Networks, Inc.         790         1.02%         103,067           General Electric Co.         3,740         0.93%         94,510           Graco, Inc.         1,260         1.00%         101,027           Health Net, Inc.         2,087         1.10%         108,512           Hill-Rom Holdings, Inc. <td></td> <td>· · · · · · · · · · · · · · · · · · ·</td> <td></td> <td></td>		· · · · · · · · · · · · · · · · · · ·		
Bunge Ltd.         1,120         1.00%         101,819           Cal-Maine Foods, Inc.         2,230         0.86%         87,037           Cardinal Health, Inc.         1,260         1.00%         101,720           Century Link, Inc.         2,520         0.98%         99,742           Chimera Investment Corp.         29,900         0.94%         95,082           Consolidated Edison, Inc.         1,560         1.01%         102,976           CVS Caremark Corp.         1,116         1.06%         107,482           Deluxe Corp.         1,640         1.01%         102,090           Entergy Corp.         1,200         1.03%         104,976           Everest Re Group Ltd.         580         0.97%         98,774           Exorn Mobil Corp.         1,090         0.99%         100,770           F5 Networks, Inc.         790         1.02%         103,60           General Electric Co.         3,740         0.93%         94,510           Graco, Inc.         1,260         1.00%         101,027           Health Net, Inc.         2,087         1.10%         111,717           Hevlett-Packard Co.         2,704         1.07%         108,512           Humana, Inc.	BlackRock, Inc.		0.92%	
Cal-Maine Foods, Inc.         2,230         0.86%         87,037           Cardinal Health, Inc.         1,260         1,00%         101,720           Century Link, Inc.         2,520         0.98%         99,742           Chimera Investment Corp.         29,900         0.94%         95,082           Consolidated Edison, Inc.         1,560         1.01%         102,976           CVS Caremark Corp.         1,116         1.06%         107,482           Deluxe Corp.         1,640         1.01%         102,090           Entergy Corp.         1,200         1.03%         104,976           Everest Re Group Ltd.         580         0.97%         98,774           Exxon Mobil Corp.         1,090         0.99%         100,770           F5 Networks, Inc.         790         1.02%         103,667           General Electric Co.         3,740         0.93%         94,510           Graco, Inc.         1,260         1.00%         101,027           Health Net, Inc.         2,087         1.10%         111,717           Hewlett-Packard Co.         2,704         1.07%         108,512           Hill-Rom Holdings, Inc.         2,240         1.01%         102,189           Ingedio	•			
Cardinal Health, Inc.         1,260         1.00%         101,720           CenturyLink, Inc.         2,520         0,98%         99,742           Chimera Investment Corp.         29,900         0.94%         95,082           Cinsolidated Edison, Inc.         1,560         1.01%         102,976           CVS Caremark Corp.         1,116         1.06%         107,482           Deluxe Corp.         1,640         1.01%         102,090           Entergy Corp.         1,200         1.03%         104,976           Everest Re Group Ltd.         580         0.97%         98,774           Exxon Mobil Corp.         1,900         0.99%         100,770           Ex Notworks, Inc.         790         1.02%         103,067           General Electric Co.         3,740         0.93%         94,510           Graco, Inc.         1,260         1.00%         101,027           Health Net, Inc.         2,087         1.10%         111,717           Hewlett-Packard Co.         2,704         1.07%         108,512           Humana, Inc.         752         1.06%         108,010           Idacorp, Inc.         1,580         1.03%         104,580           Ingedion Inc.         <	· ·	,		
Century Link, Inc.         2,520         0,98%         99,742           Chimera Investment Corp.         29,900         0,94%         95,082           Consolidated Edison, Inc.         1,560         1.01%         102,976           CVS Caremark Corp.         1,116         1.06%         107,482           Deluxe Corp.         1,640         1.01%         102,090           Entergy Corp.         1,200         1.03%         104,976           Everest Re Group Ltd.         580         0.97%         98,774           Exxon Mobil Corp.         1,090         0.99%         100,770           F5 Networks, Inc.         790         1.02%         103,067           General Electric Co.         3,740         0.93%         94,510           Graco, Inc.         1,260         1.00%         101,027           Health Net, Inc.         2,087         1.10%         111,717           Hewlett-Packard Co.         2,704         1.07%         108,512           Hill-Rom Holdings, Inc.         2,240         1.01%         102,189           Humana, Inc.         1,580         1.03%         104,580           Ingredion Inc.         1,240         1.04%         105,202           International Flavors				
Chimera Investment Corp.         29,900         0.94%         95,082           Consolidated Edison, Inc.         1,560         1.01%         102,976           CVS Caremark Corp.         1,116         1.06%         107,482           Deluxe Corp.         1,640         1.01%         102,090           Entergy Corp.         1,200         1.03%         104,976           Everest Re Group Ltd.         580         0.97%         98,774           Exxon Mobil Corp.         1,090         0.99%         100,770           F5 Networks, Inc.         790         1.02%         103,067           General Electric Co.         3,740         0.93%         94,510           Graco, Inc.         1,260         1.00%         101,027           Health Net, Inc.         2,087         1.10%         111,717           Hewlett-Packard Co.         2,704         1.07%         108,512           Hill-Rom Holdings, Inc.         2,240         1.01%         102,189           Humana, Inc.         752         1.06%         108,010           Idacorp, Inc.         1,580         1.03%         104,580           Ingredion Inc.         1,240         1.04%         105,202           International Flavors & Frag				
CVS Caremark Corp.       1,116       1.06%       107,482         Deluxe Corp.       1,640       1.01%       102,090         Entergy Corp.       1,200       1.03%       104,976         Everest Re Group Ltd.       580       0.97%       98,774         Exxon Mobil Corp.       1,090       0.99%       100,770         F5 Networks, Inc.       790       1.02%       103,067         General Electric Co.       3,740       0.93%       94,510         Graco, Inc.       1,260       1.00%       101,027         Health Net, Inc.       2,087       1.10%       111,717         Hewlett-Packard Co.       2,704       1.07%       108,512         Hill-Rom Holdings, Inc.       2,240       1.01%       102,189         Humana, Inc.       752       1.06%       108,010         Idacorp, Inc.       1,580       1.03%       104,580         Ingredion Inc.       1,240       1.04%       105,202         Intel Corp.       2,983       1.07%       108,253         International Flavors & Fragrances, Inc.       1,030       1.03%       104,401         Johnson & Johnson       920       0.95%       96,204	· · · · · · · · · · · · · · · · · · ·	29,900	0.94%	95,082
Deluxe Corp.         1,640         1.01%         102,090           Entergy Corp.         1,200         1.03%         104,976           Everest Re Group Ltd.         580         0.97%         98,774           Exxon Mobil Corp.         1,090         0.99%         100,770           F5 Networks, Inc.         790         1.02%         103,067           General Electric Co.         3,740         0.93%         94,510           Graco, Inc.         1,260         1.00%         101,027           Health Net, Inc.         2,087         1.10%         111,717           Hewlett-Packard Co.         2,704         1.07%         108,512           Hill-Rom Holdings, Inc.         2,240         1.01%         102,189           Humana, Inc.         752         1.06%         108,010           Idacorp, Inc.         1,580         1.03%         104,580           Ingredion Inc.         1,240         1.04%         105,202           Intel Corp.         2,983         1.07%         108,253           International Flavors & Fragrances, Inc.         1,030         1.03%         104,401           Johnson & Johnson         920         0.95%         96,204				
Entergy Corp.         1,200         1.03%         104,976           Everest Re Group Ltd.         580         0.97%         98,774           Exxon Mobil Corp.         1,090         0.99%         100,770           F5 Networks, Inc.         790         1.02%         103,067           General Electric Co.         3,740         0.93%         94,510           Graco, Inc.         1,260         1.00%         101,027           Health Net, Inc.         2,087         1.10%         111,717           Hewlett-Packard Co.         2,704         1.07%         108,512           Hill-Rom Holdings, Inc.         2,240         1.01%         102,189           Humana, Inc.         2,240         1.01%         108,010           Idacorp, Inc.         1,580         1.03%         104,580           Ingredion Inc.         1,240         1.04%         105,202           Intel Corp.         2,983         1.07%         108,253           International Flavors & Fragrances, Inc.         1,030         1.03%         104,401           Johnson & Johnson         920         0.95%         96,204				
Everest Re Group Ltd.       580       0.97%       98,774         Exxon Mobil Corp.       1,090       0.99%       100,770         F5 Networks, Inc.       790       1.02%       103,067         General Electric Co.       3,740       0.93%       94,510         Graco, Inc.       1,260       1.00%       101,027         Health Net, Inc.       2,087       1.10%       111,717         Hewlett-Packard Co.       2,704       1.07%       108,512         Hill-Rom Holdings, Inc.       2,240       1.01%       102,189         Humana, Inc.       752       1.06%       108,010         Idacorp, Inc.       1,580       1.03%       104,580         Ingredion Inc.       1,240       1.04%       105,202         Intel Corp.       2,983       1.07%       108,253         International Flavors & Fragrances, Inc.       1,030       1.03%       104,401         Johnson & Johnson       920       0.95%       96,204	1			
Exxon Mobil Corp.       1,090       0.99%       100,770         F5 Networks, Inc.       790       1.02%       103,067         General Electric Co.       3,740       0.93%       94,510         Graco, Inc.       1,260       1.00%       101,027         Health Net, Inc.       2,087       1.10%       111,717         Hewlett-Packard Co.       2,704       1.07%       108,512         Hill-Rom Holdings, Inc.       2,240       1.01%       102,189         Humana, Inc.       752       1.06%       108,010         Idacorp, Inc.       1,580       1.03%       104,580         Ingredion Inc.       1,240       1.04%       105,202         Intel Corp.       2,983       1.07%       108,253         International Flavors & Fragrances, Inc.       1,030       1.03%       104,401         Johnson & Johnson       920       0.95%       96,204				
General Electric Co.       3,740       0.93%       94,510         Graco, Inc.       1,260       1.00%       101,027         Health Net, Inc.       2,087       1.10%       111,717         Hewlett-Packard Co.       2,704       1.07%       108,512         Hill-Rom Holdings, Inc.       2,240       1.01%       102,189         Humana, Inc.       752       1.06%       108,010         Idacorp, Inc.       1,580       1.03%       104,580         Ingredion Inc.       1,240       1.04%       105,202         Intel Corp.       2,983       1.07%       108,253         International Flavors & Fragrances, Inc.       1,030       1.03%       104,401         Johnson & Johnson       920       0.95%       96,204	*			,
Graco, Inc.       1,260       1.00%       101,027         Health Net, Inc.       2,087       1.10%       111,717         Hewlett-Packard Co.       2,704       1.07%       108,512         Hill-Rom Holdings, Inc.       2,240       1.01%       102,189         Humana, Inc.       752       1.06%       108,010         Idacorp, Inc.       1,580       1.03%       104,580         Ingredion Inc.       1,240       1.04%       105,202         Intel Corp.       2,983       1.07%       108,253         International Flavors & Fragrances, Inc.       1,030       1.03%       104,401         Johnson & Johnson       920       0.95%       96,204				
Health Net, Inc.       2,087       1.10%       111,717         Hewlett-Packard Co.       2,704       1.07%       108,512         Hill-Rom Holdings, Inc.       2,240       1.01%       102,189         Humana, Inc.       752       1.06%       108,010         Idacorp, Inc.       1,580       1.03%       104,580         Ingredion Inc.       1,240       1.04%       105,202         Intel Corp.       2,983       1.07%       108,253         International Flavors & Fragrances, Inc.       1,030       1.03%       104,401         Johnson & Johnson       920       0.95%       96,204				
Hewlett-Packard Co.       2,704       1.07%       108,512         Hill-Rom Holdings, Inc.       2,240       1.01%       102,189         Humana, Inc.       752       1.06%       108,010         Idacorp, Inc.       1,580       1.03%       104,580         Ingredion Inc.       1,240       1.04%       105,202         Intel Corp.       2,983       1.07%       108,253         International Flavors & Fragrances, Inc.       1,030       1.03%       104,401         Johnson & Johnson       920       0.95%       96,204				
Hill-Rom Holdings, Inc.       2,240       1.01%       102,189         Humana, Inc.       752       1.06%       108,010         Idacorp, Inc.       1,580       1.03%       104,580         Ingredion Inc.       1,240       1.04%       105,202         Intel Corp.       2,983       1.07%       108,253         International Flavors & Fragrances, Inc.       1,030       1.03%       104,401         Johnson & Johnson       920       0.95%       96,204				
Humana, Inc.     752     1.06%     108,010       Idacorp, Inc.     1,580     1.03%     104,580       Ingredion Inc.     1,240     1.04%     105,202       Intel Corp.     2,983     1.07%     108,253       International Flavors & Fragrances, Inc.     1,030     1.03%     104,401       Johnson & Johnson     920     0.95%     96,204				
Ingredion Inc.       1,240       1.04%       105,202         Intel Corp.       2,983       1.07%       108,253         International Flavors & Fragrances, Inc.       1,030       1.03%       104,401         Johnson & Johnson       920       0.95%       96,204	8 7			
Intel Corp.       2,983       1.07%       108,253         International Flavors & Fragrances, Inc.       1,030       1.03%       104,401         Johnson & Johnson       920       0.95%       96,204	•			
International Flavors & Fragrances, Inc.         1,030         1.03%         104,401           Johnson & Johnson         920         0.95%         96,204	•			
Johnson & Johnson 920 0.95% 96,204				

**Annual Report and Audited Financial Statements** For the year ended 31 December 2014

## **SCHEDULES OF INVESTMENTS (continued)**

As at 31 December 2014

## **Sector Global Equity Kernel Fund (Continued)**

	Fair Value as a % of			
Investment	Units	Net Assets	Fair Value USD	
Financial Assets at Fair Value through profit or loss				
(continued)				
United States (continued)				
Lear Corp.	1,076	1.04%	105,534	
NetApp, Inc.	2,350	0.96%	97,407	
PartnerRe Ltd.	854	0.96%	97,467	
Public Service Enterprise Group, Inc.	2,414	0.98%	99,964	
SanDisk Corp.	1,016	0.98%	99,548	
Snap-On, Inc.	700	0.94%	95,718	
Sonoco Products Co.	2,370	1.02%	103,569	
Symantec Corp.	3,960	1.00%	101,594	
The Finish Line, Inc.	3,780	0.91%	91,892	
The Kroger Co.	1,580	1.00%	101,452	
Tyson Foods, Inc.	2,420	0.96%	97,018	
United Therapeutics Corp.	760	0.97%	98,412	
UnitedHealth Group, Inc.	1,050	1.05%	106,144	
Validus Holdings Ltd.	2,480	1.02%	103,069	
VF Corp.	1,340	0.99%	100,366	
Vishay Intertechnology, Inc.	7,179	1.00%	101,583	
Westar Energy, Inc.	2,540	1.03%	104,750	
Western Digital Corp.	1,014	1.11%	112,250	
Zimmer Holdings, Inc.	915	1.02%	103,779	
Total United States		56.09%	5,691,553	
Total Equities		97.10%	9,856,983	
20m 2qmao	<del></del>	>112070	3,000,500	
Contracts-for-Difference				
<u>China</u>				
China Yangtze Power Co Ltd.	68,600	0.15%	15,638	
SAIC Motor Corp. Ltd.	31,400	0.08%	8,527	
Total China		0.23%	24,165	
Total Contracts-for-Difference		0.23%	24,165	
Total Financial Assets at Fair Value through profit or loss		97.33%	9,881,148	
Total Investments at Fair Value		97.33%	9,881,148	
Cash at bank and brokers		3.08%	312,889	
Liabilities in excess of other assets		(0.41)%	(41,512)	
Total Net Assets		100.00%	10,152,525	

Annual Report and Audited Financial Statements For the year ended 31 December 2014

## **SCHEDULES OF INVESTMENTS (Continued)**

As at 31 December 2014

## **Sector Global Equity Kernel Fund (Continued)**

ALL SECURITIES ARE TRANSFERABLE SECURITIES ADMITTED TO AN OFFICIAL EXCHANGE LISTING OR TRADED ON A REGULATED MARKET EXCEPT FOR CONTRACTS-FORDIFFERENCE WHICH ARE FINANCIAL DERIVATIVE INSTRUMENTS

Analysis of Total Assets	% of Total Assets
Transferable securities admitted to an official exchange	
listing or traded on a regulated market	96.24%
Financial derivative instruments	0.24%
Other assets	3.52%
Total Assets	100.00%

**Annual Report and Audited Financial Statements** For the year ended 31 December 2014

## **SCHEDULES OF INVESTMENTS (continued)**

As at 31 December 2014

#### **Sector Healthcare Value Fund**

Primarcial Assets at Fair Value through profit or loss Equities		Fair	r Value as a % of	
Denmark	Investment	Units	Net Assets	Fair Value USD
Denmark	Financial Assets at Fair Value through profit or loss			
Hambleck A/S   120,000   4,08%   2,394,637     Total Denmark   34,000   3,02%   1,769,076     Ipane S.A.   34,000   6,41%   3,753,648     Sanofi-Aventis S.A.   41,000   6,41%   3,753,648     Total France   9,43%   5,522,741     Germany   7,840   1,83%   1,072,008     Bayer AG   7,840   1,83%   1,072,008     Total Germany   1,83%   1,072,008     Japan   Astellas Pharmaceutical Co. Ltd.   100,000   2,40%   1,406,647     Salikas Pharmaceutical Co. Ltd.   100,000   2,40%   1,548,689     Nichi-iko Pharmaceutical Co. Ltd.   30,000   1,55%   905,042     Shinongi & Co. Ltd.   30,000   1,55%   905,042     Shinongi & Co. Ltd.   30,000   1,33%   781,934     Total Japan   9,34%   5,476,573     Netherlands   9,34%   5,476,573     Netherlands   1,50%   876,681     Total Netherlands   1,50%   876,681     Total Sweden   1,13%   662,890     Total Sweden   1,13%   662,890     Total Sweden   1,13%   662,890     Total Sweden   1,13%   1,007,764     Total Sweden   1,13%   1,007,764     Total Sweden   1,13%   1,007,765     Total Sweden   1,13%   1,007,765     Total Sweden   1,13%   1,007,764     Total Sweden   1,13%   1,007,765     Total Sweden   1,13%   1,007				
Prance   P				
Paraice   Para	H Lundbeck A/S	120,000		2,394,637
Page 18	Total Denmark		4.08%	2,394,637
Sanof-Aventis S.A.         41,000         6.41%         3.753,648           Total France         9,43%         5,522,741           Germany         7,840         1.83%         1,072,008           Bayer AG         7,840         1.83%         1,072,008           Japan         8         1,000         2,40%         1,406,647           Astellas Pharmaceutical Co. Ltd.         110,000         2,40%         1,406,647           Daichi Sankyo Co. Ltd.         110,000         2,64%         1,548,689           Nichi-iko Pharmaceutical Co. Ltd.         30,000         1,55%         905,042           Shionogi & Co. Ltd.         30,000         1,55%         905,042           Shionogi & Co. Ltd.         30,000         1,55%         905,642           Shionogi & Co. Ltd.         30,000         1,55%         876,681           Total Shibit Philips Electronics NV         30,000         1,55%         876,681 <td><u>France</u></td> <td></td> <td></td> <td></td>	<u>France</u>			
Total France   9.43%   5.522,741     Germany				
Bayer AG		41,000		
Bayer AG         7,840         1.83%         1.072,008           Total Germany         1.83%         1.072,008           Japan         3         1.072,008           Astellas Pharmaceutical Co. Ltd.         100,000         2.40%         1.406,647           Discibit Sankyo Co. Ltd.         110,000         2.64%         1.548,689           Nich-is Co. Ltd.         50         0.00%         782           Discibit Sankyo Co. Ltd.         30,000         1.55%         905,042           Shionogi & Co. Ltd.         30,000         1.55%         905,042           Shionogi & Co. Ltd.         30,000         1.33%         781,934           Takeda Pharmaceutical Co. Ltd.         20,000         1.42%         833,479           Total Japan         30,000         1.50%         876,681           Netherlands         30,000         1.50%         876,681           Total Netherlands         30,000         1.50%         876,681           Sweden         2         1.13%         662,890           Getinge AB         29,186         1.13%         662,890           Total Sweden         9,000         1.78%         1,044,332           Basilea Pharmaceutica AG         6,000         0.95%	Total France		9.43%	5,522,741
Total Germany		7.940	1 920/	1 072 009
Astellas Pharmaceutical Co. Ltd.	·	7,040		
Astellas Pharmaceutical Co. Ltd.	•		1.0370	1,072,000
Daichi Sankyo Co. Ltd.         110,000         2,64%         1,548,689           Nichi-iko Pharmaceutical Co. Ltd.         50         0.00%         782           Otsuka Holdings Co. Ltd.         30,000         1.55%         905,042           Shionogi & Co. Ltd.         30,000         1.33%         781,934           Takeda Pharmaceutical Co. Ltd.         20,000         1.42%         833,479           Total Japan         30,000         1.50%         876,681           Netherlands         30,000         1.50%         876,681           Total Netherlands         29,186         1.50%         876,681           Sweden         29,186         1.13%         662,890           Total Sweden         29,186         1.13%         662,890           Switzerland         9,000         1.78%         1,044,332           Basilea Pharmaceutica AG         6,000         0.95%         556,433           Total Switzerland         22,73%         1,600,765           United Kingdom         22,73%         1,600,765           United Kingdom         3.40%         1,988,86           GlaxoSmithKline PLC         5,000         1.83%         1,072,764           Total United Kingdom         8,500         1.3		100 000	2 40%	1 406 647
Orsuka Holdings Co. Ltd.         30,000         1.55%         905,042           Shionogi & Co. Ltd.         30,000         1.33%         781,934           Takeda Pharmaceutical Co. Ltd.         20,000         1.42%         833,479           Total Japan         9,34%         5,476,573           Netherlands         30,000         1.50%         876,681           Koninklijke Philips Electronics NV         30,000         1.50%         876,681           Total Netherlands         29,186         1.13%         662,890           Sweden         29,186         1.13%         662,890           Total Sweden         9,000         1.78%         1,044,332           Basilea Pharmaceutica AG         6,000         0.95%         556,433           Total Switzerland         2,000         3.40%         1,988,886           Glaxo SmithKline PLC         28,000         3.40%         1,988,886           Glaxo SmithKline PLC         50,000         1.83%         1,072,764           Total United Kingdom         8,500         1,33%         1,072,764           Total Lunited Ingdom         8,500         1,33%         1,072,764           Total Cortect         8,500         1,33%         1,072,764		, , , , , , , , , , , , , , , , , , ,		
Shionogi & Co. Ltd.         30,000         1.33%         781,934           Takeda Pharmaceutical Co. Ltd.         20,000         1.42%         833,479           Total Japan         9,34%         5,476,573           Netherlands         30,000         1.50%         876,681           Koninklijke Philips Electronics NV         30,000         1.50%         876,681           Sweden         29,186         1.13%         662,890           Getinge AB         29,186         1.13%         662,890           Switzerland         9,000         1.78%         1,044,332           Basilea Pharmaceutica AG         6,000         0.95%         556,433           Total Switzerland         28,000         3,40%         1,988,886           Glaxo Smith Kline PLC         28,000         3,40%         1,988,886           Glaxo Smith Kline PLC         50,000         1.83%         1,072,764           Total United Kingdom         8,500         1.83%         1,072,764           Amerisource Bergen Corp.         8,500         1.31%         766,360           Baxter International, Inc.         48,000         6,00%         3,517,920           Bio-Rad Laboratories, Inc.         9,000         1.85%         1,085,040			0.00%	
Takeda Pharmaceutical Co. Ltd.         20,000         1.42%         833,479           Total Japan         9,34%         5,476,573           Netherlands         30,000         1.50%         876,681           Koninklijke Philips Electronics NV         30,000         1.50%         876,681           Total Netherlands         29,186         1.13%         662,890           Sweden         1.13%         662,890           Total Sweden         9,000         1.78%         1,044,332           Actelion Ltd.         9,000         1.78%         1,044,332           Basilea Pharmaceutica AG         6,000         0.95%         556,433           Total Switzerland         2,73%         1,600,765           United Kingdom         28,000         3.40%         1,988,86           GlaxoSmithKline PLC         28,000         3.40%         1,988,86           GlaxoSmithKline PLC         50,000         1.83%         1,072,764           Total United States         3,000         3.50         3.50         3.50         3.50         3.50         3.50         3.517,220         3.64,375         3.517,220         3.64,375         3.517,220         3.64,375         3.517,220         3.64,375         3.643,750         3.517,220 </td <td></td> <td></td> <td></td> <td></td>				
Total Japan         9.34%         5,476,573           Netherlands         Koninklijke Philips Electronics NV         30,000         1.50%         876,681           Total Netherlands         1.50%         876,681           Sweden         29,186         1.13%         662,890           Total Sweden         29,000         1.78%         1,044,332           Basilea Pharmaceutica AG         6,000         0.95%         556,433           Total Switzerland         2,73%         1,600,765           United Kingdom         28,000         3.40%         1,988,886           GlaxoSmithKline PLC         28,000         3.40%         1,988,886           GlaxoSmithKline pLC         50,000         1.83%         1,072,764           Total United Kingdom         5.23%         3,061,650           United States         3         3,000         3.517,920           Baxter International, Inc.         8,500         1.31%         766,360           Baxter International, Inc.         48,000         6.0%         3,517,920           Bio-Rad Laboratories, Inc.         9,000         1.85%         1,085,040           Boston Scientific Corp.         275,000         6.22%         3,643,750           Bristol-Myers Squibb Co.<				
Netherlands   Noninklijke Philips Electronics NV   30,000   1.50%   876,681   1.50%   876,681   1.50%   876,681   1.50%   876,681   1.50%   876,681   1.50%   876,681   1.50%   876,681   1.50%   876,681   1.50%   876,681   1.50%   876,681   1.13%   662,890   1.13%   662,890   1.13%   662,890   1.13%   662,890   1.13%   662,890   1.13%   662,890   1.13%   1.044,332   1.041,33		20,000		
Koninklijke Philips Electronics NV         30,000         1.50%         876,681           Total Netherlands         1.50%         876,681           Sweden         Sweden           Getinge AB         29,186         1.13%         662,890           Total Sweden         9,000         1.78%         1,044,332           Basilea Pharmaceutica AG         6,000         0.95%         556,433           Total Switzerland         2,000         1.78%         1,044,332           Basilea Pharmaceutica AG         6,000         0.95%         556,433           Total Switzerland         2,000         3.40%         1,988,886           Glaxo Smith Kline PLC         28,000         3.40%         1,988,886           Glaxo Smith Kline PLC         50,000         1.83%         1,072,764           Total United Kingdom         8,500         1.83%         1,072,764           Total United States         8,500         1.31%         766,360           Baxter International, Inc.         48,000         6,00%         3,517,920           Bio- Rad Laboratories, Inc.         9,000         1.85%         1,085,040           Bots on Scientific Corp.         275,000         6,22%         3,643,750           Bristol-M	•		9.5470	3,470,373
Sweden Getinge AB         29,186         1.13%         662,890           Total Sweden         1.13%         662,890           Switzerland         1.13%         662,890           Switzerland         9,000         1.78%         1,044,332           Basilea Pharmaceutica AG         6,000         0.95%         556,433           Total Switzerland         2,73%         1,600,765           United Kingdom         8         2,73%         1,600,765           United Kingdom         28,000         3,40%         1,988,886           GlaxoSmithKline PLC         50,000         1.83%         1,072,764           Total United Kingdom         5,23%         3,061,650           United States         8,500         1.31%         766,360           Baxter International, Inc.         48,000         6,00%         3,517,920           Bio-Rad Laboratories, Inc.         9,000         1.85%         1,085,040           Boston Scientific Corp.         275,000         6,22%         3,643,750           Bristol-Myers Squibb Co.         38,000         3,83%         2,243,140           Cardinal Health, Inc.         16,000         2,21%         1,291,680           Cigna Corp.         9,000         1.58%		30,000	1 500%	976 691
Sweden Getinge AB         29,186         1.13%         662,890           Total Sweden         1.13%         662,890           Switzerland Actelion Ltd.         9,000         1.78%         1,044,332           Basilea Pharmaceutica AG         6,000         0.95%         556,433           Total Switzerland         2,73%         1,600,765           United Kingdom         3,40%         1,988,886           GlaxOSmithKline PLC         28,000         3,40%         1,988,886           GlaxOSmithKline PLC         50,000         1.83%         1,072,764           Total United Kingdom         5,23%         3,061,650           United States         8         1,31%         766,360           MarerisourceBergen Corp.         8,500         1,31%         766,360           Baxter International, Inc.         48,000         6,00%         3,517,920           Bio-Rad Laboratories, Inc.         9,000         1,85%         1,085,040           Boston Scientific Corp.         275,000         6,22%         3,643,750           Bristol-Myers Squibb Co.         38,000         3,83%         2,243,140           Cardinal Health, Inc.         16,000         2,21%         1,291,680           Cigna Corp.         9,000 <td>* *</td> <td>30,000</td> <td></td> <td>,</td>	* *	30,000		,
Getinge AB         29,186         1.13%         662,890           Total Sweden         1.13%         662,890           Switzerland			1.5070	870,081
Switzerland         1.13%         662,890           Switzerland         9,000         1.78%         1,044,332           Basilea Pharmaceutica AG         6,000         0.95%         556,433           Total Switzerland         2,73%         1,600,765           United Kingdom         28,000         3,40%         1,988,886           GlaxoSmithKline PLC         50,000         1.83%         1,072,764           Total United Kingdom         5,23%         3,061,650           United States         8,500         1.31%         766,360           Baxter International, Inc.         48,000         6,00%         3,517,920           Bio-Rad Laboratories, Inc.         9,000         1.85%         1,085,040           Boston Scientific Corp.         275,000         6,22%         3,643,750           Bristol-Myers Squibb Co.         38,000         3,83%         2,243,140           Cardinal Health, Inc.         16,000         2,21%         1,291,680           Cigna Corp.         9,000         1.58%         926,190           Community Health Systems, Inc.         9,000         0.83%         485,280           Edwards Lifesciences Corp.         10,000         2,17%         1,273,800           Eli Lilly & Co. <td></td> <td>20 186</td> <td>1 13%</td> <td>662 890</td>		20 186	1 13%	662 890
Actelion Ltd.	•	27,100		
Actelion Ltd.         9,000         1.78%         1,044,332           Basilea Pharmaceutica AG         6,000         0.95%         556,433           Total Switzerland         2.73%         1,600,765           United Kingdom         28,000         3.40%         1,988,886           GlaxoSmithKline PLC         50,000         1.83%         1,072,764           Total United Kingdom         5.23%         3,061,650           United States         8,500         1.31%         766,360           Baxter International, Inc.         48,000         6.00%         3,517,920           Bio-Rad Laboratories, Inc.         9,000         1.85%         1,085,040           Boston Scientific Corp.         275,000         6.22%         3,643,750           Bristol-Myers Squibb Co.         38,000         3.83%         2,243,140           Cardinal Health, Inc.         16,000         2.21%         1,291,680           Cigna Corp.         9,000         1.58%         926,190           Community Health Systems, Inc.         9,000         0.83%         485,280           Edwards Lifesciences Corp.         10,000         2.17%         1,273,800           Eli Lilly & Co.         46,000         5.42%         3,173,540 <td></td> <td></td> <td></td> <td></td>				
Basilea Pharmaceutica AG         6,000         0.95%         556,433           Total Switzerland         2.73%         1,600,765           United Kingdom         8         3.40%         1,988,886           GlaxoSmithKline PLC         50,000         1.83%         1,072,764           Total United Kingdom         5.23%         3,061,650           United States         8,500         1.31%         766,360           AmerisourceBergen Corp.         48,000         6,00%         3,517,920           Bio-Rad Laboratories, Inc.         9,000         1.85%         1,085,040           Boston Scientific Corp.         275,000         6,22%         3,643,750           Bristol-Myers Squibb Co.         38,000         3,83%         2,243,140           Cardinal Health, Inc.         16,000         2,21%         1,291,680           Cigna Corp.         9,000         1.58%         926,190           Community Health Systems, Inc.         9,000         0.83%         485,280           Edwards Lifesciences Corp.         10,000         2.17%         1,273,800           Eli Lilly & Co.         46,000         5,42%         3,173,540		9.000	1 78%	1 044 332
United Kingdom         2.73%         1,600,765           AstraZeneca PLC         28,000         3.40%         1,988,886           GlaxoSmithKline PLC         50,000         1.83%         1,072,764           Total United Kingdom         5.23%         3,061,650           United States         Valuation of the company of				
AstraZeneca PLC         28,000         3.40%         1,988,886           GlaxoSmithKline PLC         50,000         1.83%         1,072,764           Total United Kingdom         52,23%         3,061,650           United States         States         States           AmerisourceBergen Corp.         8,500         1.31%         766,360           Baxter International, Inc.         48,000         6.00%         3,517,920           Bio-Rad Laboratories, Inc.         9,000         1.85%         1,085,040           Boston Scientific Corp.         275,000         6.22%         3,643,750           Bristol-Myers Squibb Co.         38,000         3.83%         2,243,140           Cardinal Health, Inc.         16,000         2.21%         1,291,680           Cigna Corp.         9,000         1.58%         926,190           Community Health Systems, Inc.         9,000         0.83%         485,280           Edwards Lifesciences Corp.         10,000         2.17%         1,273,800           Eli Lilly & Co.         46,000         5.42%         3,173,540	Total Switzerland	· <u>-</u>		
AstraZeneca PLC         28,000         3.40%         1,988,886           GlaxoSmithKline PLC         50,000         1.83%         1,072,764           Total United Kingdom         52,23%         3,061,650           United States         States         States           AmerisourceBergen Corp.         8,500         1.31%         766,360           Baxter International, Inc.         48,000         6.00%         3,517,920           Bio-Rad Laboratories, Inc.         9,000         1.85%         1,085,040           Boston Scientific Corp.         275,000         6.22%         3,643,750           Bristol-Myers Squibb Co.         38,000         3.83%         2,243,140           Cardinal Health, Inc.         16,000         2.21%         1,291,680           Cigna Corp.         9,000         1.58%         926,190           Community Health Systems, Inc.         9,000         0.83%         485,280           Edwards Lifesciences Corp.         10,000         2.17%         1,273,800           Eli Lilly & Co.         46,000         5.42%         3,173,540	United Kingdom			
Total United Kingdom         5.23%         3,061,650           United States         8,500         1.31%         766,360           Baxter International, Inc.         48,000         6.00%         3,517,920           Bio-Rad Laboratories, Inc.         9,000         1.85%         1,085,040           Boston Scientific Corp.         275,000         6.22%         3,643,750           Bristol-Myers Squibb Co.         38,000         3.83%         2,243,140           Cardinal Health, Inc.         16,000         2.21%         1,291,680           Cigna Corp.         9,000         1.58%         926,190           Community Health Systems, Inc.         9,000         0.83%         485,280           Edwards Lifesciences Corp.         10,000         2.17%         1,273,800           Eli Lilly & Co.         46,000         5.42%         3,173,540		28,000	3.40%	1,988,886
United States           AmerisourceBergen Corp.         8,500         1.31%         766,360           Baxter International, Inc.         48,000         6.00%         3,517,920           Bio-Rad Laboratories, Inc.         9,000         1.85%         1,085,040           Boston Scientific Corp.         275,000         6.22%         3,643,750           Bristol-Myers Squibb Co.         38,000         3.83%         2,243,140           Cardinal Health, Inc.         16,000         2.21%         1,291,680           Cigna Corp.         9,000         1.58%         926,190           Community Health Systems, Inc.         9,000         0.83%         485,280           Edwards Lifesciences Corp.         10,000         2.17%         1,273,800           Eli Lilly & Co.         46,000         5.42%         3,173,540	GlaxoSmithKline PLC	50,000	1.83%	
Amerisource Bergen Corp.       8,500       1.31%       766,360         Baxter International, Inc.       48,000       6.00%       3,517,920         Bio-Rad Laboratories, Inc.       9,000       1.85%       1,085,040         Boston Scientific Corp.       275,000       6.22%       3,643,750         Bristol-Myers Squibb Co.       38,000       3.83%       2,243,140         Cardinal Health, Inc.       16,000       2.21%       1,291,680         Cigna Corp.       9,000       1.58%       926,190         Community Health Systems, Inc.       9,000       0.83%       485,280         Edwards Lifesciences Corp.       10,000       2.17%       1,273,800         Eli Lilly & Co.       46,000       5.42%       3,173,540	Total United Kingdom		5.23%	3,061,650
Baxter International, Inc.       48,000       6.00%       3,517,920         Bio-Rad Laboratories, Inc.       9,000       1.85%       1,085,040         Boston Scientific Corp.       275,000       6.22%       3,643,750         Bristol-Myers Squibb Co.       38,000       3.83%       2,243,140         Cardinal Health, Inc.       16,000       2.21%       1,291,680         Cigna Corp.       9,000       1.58%       926,190         Community Health Systems, Inc.       9,000       0.83%       485,280         Edwards Lifesciences Corp.       10,000       2.17%       1,273,800         Eli Lilly & Co.       46,000       5.42%       3,173,540	<u>United States</u>			
Bio-Rad Laboratories, Inc.       9,000       1.85%       1,085,040         Boston Scientific Corp.       275,000       6.22%       3,643,750         Bristol-Myers Squibb Co.       38,000       3.83%       2,243,140         Cardinal Health, Inc.       16,000       2.21%       1,291,680         Cigna Corp.       9,000       1.58%       926,190         Community Health Systems, Inc.       9,000       0.83%       485,280         Edwards Lifesciences Corp.       10,000       2.17%       1,273,800         Eli Lilly & Co.       46,000       5.42%       3,173,540				
Boston Scientific Corp.       275,000       6.22%       3,643,750         Bristol-Myers Squibb Co.       38,000       3.83%       2,243,140         Cardinal Health, Inc.       16,000       2.21%       1,291,680         Cigna Corp.       9,000       1.58%       926,190         Community Health Systems, Inc.       9,000       0.83%       485,280         Edwards Lifesciences Corp.       10,000       2.17%       1,273,800         Eli Lilly & Co.       46,000       5.42%       3,173,540				
Bristol-Myers Squibb Co.       38,000       3.83%       2,243,140         Cardinal Health, Inc.       16,000       2.21%       1,291,680         Cigna Corp.       9,000       1.58%       926,190         Community Health Systems, Inc.       9,000       0.83%       485,280         Edwards Lifesciences Corp.       10,000       2.17%       1,273,800         Eli Lilly & Co.       46,000       5.42%       3,173,540				
Cardinal Health, Inc.       16,000       2.21%       1,291,680         Cigna Corp.       9,000       1.58%       926,190         Community Health Systems, Inc.       9,000       0.83%       485,280         Edwards Lifesciences Corp.       10,000       2.17%       1,273,800         Eli Lilly & Co.       46,000       5.42%       3,173,540				
Cigna Corp.       9,000       1.58%       926,190         Community Health Systems, Inc.       9,000       0.83%       485,280         Edwards Lifesciences Corp.       10,000       2.17%       1,273,800         Eli Lilly & Co.       46,000       5.42%       3,173,540				
Edwards Lifesciences Corp.       10,000       2.17%       1,273,800         Eli Lilly & Co.       46,000       5.42%       3,173,540				
Eli Lilly & Co. 46,000 5.42% 3,173,540	Community Health Systems, Inc.	9,000	0.83%	485,280
Hospira, Inc.       27,000       2.82%       1,653,750         Integra LifeSciences Holdings Corp.       20,000       1.85%       1,084,600				
Integra LifeSciences Holdings Corp.         20,000         1.85%         1,084,600           Ironwood Pharmaceuticals, Inc.         95,000         2.48%         1,455,400				
LifePoint Hospitals, Inc. 15,000 1.84% 1,078,650				
Masimo Corp. 30,000 1.35% 790,200	1 '			
Mylan, Inc. 19,000 1.83% 1,071,030	*			
Patterson Cos., Inc. 12,000 0.99% 577,200				
PerkinElmer, Inc. 30,000 2.24% 1,311,900	PerkinElmer, Inc.	30,000	2.24%	1,311,900
Quest Diagnostics, Inc.         14,000         1.60%         938,840	Quest Diagnostics, Inc.	14,000	1.60%	938,840

Annual Report and Audited Financial Statements For the year ended 31 December 2014

## **SCHEDULES OF INVESTMENTS (continued)**

As at 31 December 2014

## **Sector Healthcare Value Fund (Continued)**

,	Fa	air Value as a % of	
Investment	Units	Net Assets	Fair Value USD
Financial Assets at Fair Value through profit or loss			
(continued)			
<u>United States (continued)</u>			
Rite Aid Corp.	100,000	1.28%	752,000
Spectrum Pharmaceuticals, Inc.	44,500	0.53%	308,385
Stryker Corp.	21,000	3.38%	1,980,930
Tenet Healthcare Corp.	24,000	2.08%	1,216,080
The Medicines Co.	27,000	1.28%	747,090
Thoratec Corp.	35,000	1.94%	1,136,100
Vertex Pharmaceuticals, Inc.	11,000	2.23%	1,306,800
WellCare Health Plans, Inc.	16,000	2.24%	1,312,960
Total United States	_	63.38%	37,128,615
Total Equities		98.65%	57,796,560
Total Financial Assets at Fair Value through profit or loss	_	98.65%	57,796,560
Financial Liabilities at Fair Value through profit or loss			
Net unrealised loss on forward foreign currency contracts (note 7)	_	(0.47)%	(276,068)
Total Financial Liabilities at Fair Value through profit or loss		(0.47)%	(276,068)
Total I mandan Zimomete at I an Amade and provided 1000	_	(0.11)/0	(270,000)
<b>Total Investments at Fair Value</b>		98.18%	57,520,492
Cash at bank and brokers		6.90%	4,040,923
Liabilities in excess of other assets		(5.08)%	(2,975,106)
Total Net Assets	_	100.00%	58,586,309

ALL SECURITIES ARE TRANSFERABLE SECURITIES ADMITTED TO AN OFFICIAL EXCHANGE LISTING OR TRADED ON A REGULATED MARKET EXCEPT FOR FORWARD FOREIGN CURRENCY CONTRACTS WHICH ARE FINANCIAL DERIVATIVE INSTRUMENTS

Analysis of Total Assets	% of Total Assets
Transferable securities admitted to an official exchange	
listing or traded on a regulated market	93.33%
Other assets	6.67%
Total Assets	100.00%

**Annual Report and Audited Financial Statements** For the year ended 31 December 2014

## **SCHEDULES OF INVESTMENTS (continued)**

As at 31 December 2014

## Sector Sigma Nordic Fund

Sector Sigma Northe Fund	Fair	· Value as a % of	
Investment	Units	Net Assets	Fair Value NOK
<u>Financial Assets at Fair Value through profit or loss</u> Equities			
Denmark			
Danske Bank A/S	41,000	2.55%	8,362,167
Novo Nordisk A/S	28,000	2.70%	8,879,975
Royal UNIBREW A/S	7,000	2.82%	9,270,584
Topdanmark A/S	34,000	2.52%	8,293,207
Total Denmark		10.59%	34,805,933
<u>Finland</u>			
Amer Sports Oyj	56,000	2.48%	8,159,363
Huhtamaki Oyj	44,000	2.65%	8,718,223
Total Finland		5.13%	16,877,586
Norway	444.000	4.0.	
Aurora LPG Holding AS	121,890	1.95%	6,399,225
Marine Harvest ASA Opera Software ASA	141,000 126,000	4.42% 3.64%	14,508,900
Salmar ASA	80,000	3.10%	11,970,000 10,200,000
Telenor ASA	55,000	2.54%	8,332,500
Tomra Systems ASA	150,000	2.63%	8,625,000
Yara International ASA	26,000	2.64%	8,678,800
Total Norway		20.92%	68,714,425
Sweden			
AarhusKarlshamn AB	21,200	2.58%	8,477,095
Assa Abloy AB	23,000	2.78%	9,137,371
Autoliv, Inc.	10,800	2.64%	8,662,899
Hennes & Mauritz AB	31,400	2.98%	9,791,940
Hexagon AB	36,600	2.58%	8,483,033
Hexpol AB	12,604	2.71%	8,890,697
Investor AB Skandinaviska Enskilda Banken AB	33,000 121,000	2.74% 3.51%	8,998,209 11,536,693
SKF AB	54,000	2.60%	8,528,430
Swedbank AB	43,000	2.45%	8,051,372
Total Sweden		27.57%	90,557,739
Total Equities		64.21%	210,955,683
Contracts-for-Difference			
<u>Denmark</u>			
Carlsberg AS	(13,700)	0.25%	806,244
Norway			
Statoil ASA	(61,000)	0.03%	97,147
TGS Nopec Geophysical Co. ASA	(52,500)	0.13%	423,062
Total Norway		0.16%	520,209
Bermuda Avance Gas Holding Ltd.	(61,000)	0.12%	381,952
Avaice das Holding Etd.	(01,000)		301,732
Total Contracts-for-Difference		0.53%	1,708,405
Options			
February 15 Puts on OBX Put 460 19/02/2015	600	0.05%	172,500
January 15 Puts on OBX Put 480 15/01/2015	1,000	0.03%	87,500
January 15 Puts on OBX Put 490 15/01/2015	1,000	0.05%	150,000
January 15 Puts on OMX Put 1380 16/01/2015 January 15 Puts on OMX Put 1390 16/01/2015	250 250	0.03%	92,184
January 15 Puts on OMX Put 1390 16/01/2015  Total Options	250	0.03% <b>0.19%</b>	86,198 <b>588,382</b>
Total Options		0.19%	300,384

Annual Report and Audited Financial Statements For the year ended 31 December 2014

## **SCHEDULES OF INVESTMENTS (continued)**

As at 31 December 2014

Sector Sigma Nordic Fund (Continued)

Investment	Units	Fair Value as a % of Net Assets	Fair Value NOK
Financial Assets at Fair Value through profit or loss	Omis	Net Assets	ran value NOK
(continued)			
Net unrealised gain on forward foreign currency contracts (note 7)		0.08%	289,506
Total Financial Assets at Fair Value through profit or loss		65.01%	213,541,976
<u>Financial Liabilities at Fair Value through profit or loss</u> Contracts-for-Difference			
Norway DNB ASA	(74,000)	(0.01)%	(22,589)
<u>Finland</u> Wartsila Oyj	(22,000)	(0.01)%	(43,180)
<u>Denmark</u> Trygvesta AS	(8,900)	(0.03)%	(85,118)
Total Contracts-for-Difference		(0.05)%	(150,887)
Total Financial Liabilities at Fair Value through profit or loss		(0.05)%	(150,887)
Total Investments at Fair Value		64.96%	213,391,089
Cash at bank and brokers Liabilities in excess of other assets		36.92% (1.88)%	121,267,741 (6,158,055)
Total Net Assets		100.00%	328,500,775

<sup>\*</sup> Securities pledged, in whole or in part, as margin to cover derivative contracts-for-difference trading.

ALL SECURITIES ARE TRANSFERABLE SECURITIES ADMITTED TO AN OFFICIAL EXCHANGE LISTING OR TRADED ON A REGULATED MARKET EXCEPT FOR CONTRACTS-FOR-DIFFERENCE, FORWARD FOREIGN CURRENCY CONTRACTS AND OPTIONS WHICH ARE FINANCIAL DERIVATIVE INSTRUMENTS

Analysis of Total Assets	% of Total Assets
Transferable securities admitted to an official exchange	
listing or traded on a regulated market	62.51%
Financial derivative instruments	0.77%
Other assets	36.72%
Total Assets	100.00%

Annual Report and Audited Financial Statements For the year ended 31 December 2014

#### NOTES TO THE FINANCIAL STATEMENTS

#### 1. Organisation and Structure

Sector Capital Funds plc (the "Company") was incorporated and registered in Ireland under the Companies Act, 1963 to 2013 as an open-ended umbrella investment company with variable capital and with segregated liability between sub-funds on 27 September 2010 with registered number 489443. The Company is authorised by the Central Bank of Ireland pursuant to European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations 2011 (the "UCITS Regulations").

As at 31 December 2014, the Company has three funds in existence (31 December 2013: two), Sector Global Equity Kernel Fund, Sector Healthcare Value Fund and Sector Sigma Nordic Fund (the "Funds").

Sector Healthcare Value Fund commenced trading on 17 November 2010. The base currency of Sector Healthcare Value Fund is U.S. Dollars ("USD"). As at 31 December 2014, five classes are currently subscribed to in the Fund (31 December 2013: five), Class A EUR Shares, Class A NOK Shares, Class A USD Shares, Class A USD Shares, Class A NOK Shares and Class A USD Shares were listed on the Irish Stock Exchange on 18 November 2010 and Class B NOK Shares on 10 September 2013.

Sector Sigma Nordic Fund commenced trading on 25 June 2012. The base currency of Sector Sigma Nordic Fund is Norwegian Krone ("NOK"). As at 31 December 2014, seven classes are currently subscribed to in the Fund (31 December 2013: six), Class A EUR Shares, Class A NOK Shares, Class A USD Shares, Class B EUR Shares, Class B NOK Shares, Class C NOK Shares and Class L NOK Shares. Class A EUR Shares launched on 27 March 2014 and Class A USD Shares launched on 7 May 2014. No application has been made to list the shares on any stock exchange. Class B USD shares were fully redeemed during September 2014.

Sector Global Equity Kernel Fund commenced trading on 19 March 2014. The base currency of Sector Global Equity Kernel Fund is U.S. Dollars ("USD"). As at 31 December 2014, three classes are currently subscribed to in the Fund, Class L NOK, Class O NOK Shares and Class P USD Shares. Class P USD Shares were listed on the Irish Stock Exchange on 27 March 2014.

#### **Investment Objective**

The investment objective of the Sector Global Equity Kernel Fund is to maximize long-term total return relative to MSCI ACWI Index (the "Index"). The Index is a free float-adjusted market capitalisation weighted index that is designed to measure the equity market performance of developed and emerging markets. The MSCI ACWI consists of 45 country indices comprising 24 developed and 21 emerging market country indices. There can be no guarantee that the investment objective of the Fund will be achieved.

The investment objective of Sector Healthcare Value Fund is to achieve attractive long term investment returns relative to the MSCI Daily TR World Net Health Care USD (the "Index"). The Index is a capitalisation weighted index that monitors the performance of health care stocks from around the world. The Fund may invest in equities and financial instruments that are not part of the Index. There can be no guarantee that the investment objective of the Fund will be achieved.

The investment objective of Sector Sigma Nordic Fund is to generate attractive risk adjusted return for its investors, primarily through investment in Norway, Sweden, Denmark, Finland and Iceland (the "Nordic Region") with the aim of generating positive return over time in rising as well as falling equity markets. There can be no guarantee that the investment objective of the Fund will be achieved.

#### 2. Summary of Significant Accounting Policies

The financial statements have been prepared in accordance with the accounting standards generally accepted in Ireland and Irish Statute comprising the Companies Acts, 1963 to 2013 and all regulations to be construed as one with those Acts, including the Regulations. Accounting standards generally accepted in Ireland are those issued by the Financial Reporting Council and promulgated by the Institute of Chartered Accountants of Ireland. The financial statements have been prepared under the historical cost convention, as modified by the revaluation of financial assets and financial liabilities at fair value through profit or loss.

The format and certain wording of the financial statements have been adapted from those contained in the Companies (Amendment) Act 1986 and in Financial Reporting Standard 3: Reporting Financial Performance ("FRS 3") so that, in the opinion of the Directors, they more appropriately reflect the nature of the Company's business as an investment Company. The Company has availed of the exemption available to open-ended investment funds under FRS 1 "Cash Flow Statements" not to prepare a cash flow statement.

The policy set out in the prospectus provides for investments quoted, listed or dealt in on a market to be calculated by reference to the last traded price. Financial Reporting Standard 26: Financial Instruments: Measurement ("FRS 26") requires securities to be valued using bid prices for long positions and ask prices for short positions. As at 31 December 2014 and 31 December 2013 there was no material difference between the reported Net Asset Value of the Funds and the valuation required by FRS 26.

Annual Report and Audited Financial Statements For the year ended 31 December 2014

#### NOTES TO THE FINANCIAL STATEMENTS (Continued)

#### 2. Summary of Significant Accounting Policies (Continued)

#### (a) Portfolio valuation

Investment transactions

#### (i) Classification

The Company has adopted Financial Reporting Standard 25: Financial Instruments Presentation ("FRS 25"), FRS 26 and Financial Reporting Standard 29: Financial Instruments Disclosures ("FRS 29") and accordingly all its investment securities and all derivatives are classified as held for trading and are fair valued through profit or loss.

Held for trading: These include financial assets or financial liabilities that are held for the purpose of short term profit making and include forward foreign exchange contracts. Derivatives are categorised as held for trading as the Company does not designate any derivatives as hedging instruments for hedge accounting purposes under FRS 26.

Designated at fair value through profit or loss: These include financial assets or financial liabilities that are not held for trading, such as investment funds. These financial instruments are designated on the basis that their fair value can be reliably measured and their performance has been evaluated on a fair value basis in accordance with the risk management and/or investment strategy as set out in the Company's prospectus.

Financial assets that are balances due from brokers and accounts receivable are classified as loans and receivables.

#### (ii) Recognition

The Company recognises financial assets and financial liabilities on the date it becomes party to the contractual provisions of the instrument. Investment transactions are accounted for on a trade date basis at cost. Purchases and sales of securities are accounted for on the trade date on which the transaction takes place. Transaction costs are expensed immediately to the Profit and Loss Account and not capitalised as part of cost of the investment.

#### (iii) Measurement

Financial assets and financial liabilities held for trading are measured at fair value. Fair value is the amount for which an asset could be exchanged, or a liability settled, between knowledgeable, willing parties in an arms length transaction.

Realised gains and losses on sales of investments are calculated on a First-In, First-Out ("FIFO") basis. Unrealised gains and losses on investments are recognised in the Profit and Loss Account. Forward foreign currency contracts and any other instruments held by the Company and traded on an exchange will be measured at fair value based on the last reported traded price on such regulated market as at the relevant valuation point.

If an investment is quoted, listed or normally dealt in on more than one market, the Directors may, in their absolute discretion, select any of such markets for the valuation purposes.

#### (iv) Derecognition

The Company derecognises a financial asset when the contractual rights to the cash flows from the financial asset expire or it transfers the financial asset and the transfer qualifies for derecognition in accordance with FRS 25.

A financial liability is derecognised when the obligation specified in the contract is discharged, cancelled or expired.

#### (b) Forward foreign currency contracts

The unrealised gain or loss on open forward foreign currency contracts is calculated by reference to the difference between the contracted rate and the rate to close out the contract. Realised gains or losses include net gains on contracts which have been settled or offset by other contracts.

### (c) Options

When the Company writes or purchases put or call options, an amount equal to the premium received or paid is recorded as a liability or an asset and is subsequently marked-to-market based on quoted market prices in the Balance Sheet. Premiums received or paid from writing or purchasing put or call options which are expired or were unexercised are recognised on the expiration date as realised gains or losses in the Profit or Loss Account. If an option is exercised, the premium received or paid is included with the proceeds or the cost of the transaction to determine whether the Company has realised a gain or loss on the related investment transaction in the Profit and Loss Account. When the Company enters into a closing transaction, the Company will realise a gain or loss in the Profit or Loss Account depending upon whether the amount from the closing transaction is greater or less than the premium received or paid.

Annual Report and Audited Financial Statements For the year ended 31 December 2014

## NOTES TO THE FINANCIAL STATEMENTS (Continued)

#### 2. Summary of Significant Accounting Policies (Continued)

#### (d) Contracts-for-difference

A contract-for-difference ("CFD") is a contract between two parties, buyer and seller, stipulating that the seller will pay to the buyer the difference between the current value of an asset (a security, instrument, basket or index) and its value at contract time. The payment flows are usually netted against each other, with the differences being paid by one party to the other. The unrealised gain or loss depends upon the prices at which the underlying financial instruments of the CFD is valued at and is included in the Profit and Loss Account.

#### (e) Foreign exchange translation

Items included in the Company's financial statements are measured using the currency of the primary economic environment in which it operates (the "functional currency"). The functional currency of Sector Global Equity Kernel Fund is the United States Dollar ("USD"), due to the fact that the majority of the Fund's assets are denominated in USD and that a substantial portion of capital is issued in USD. The functional currency of Sector Healthcare Value Fund is the United States Dollar ("USD"), due to the fact that the majority of the Fund's assets are denominated in USD and that a substantial portion of capital is issued in USD. Sector Sigma Nordic Fund is denominated in Norwegian Krone ("NOK"), due to the fact that the majority of the Fund's assets are denominated in NOK and that a substantial portion of capital is issued in NOK. Each Fund has adopted its functional currency as the presentation currency for these financial statements. Assets and liabilities expressed in foreign currencies are converted into the functional currency of each Fund using the exchange rates prevailing as at the balance sheet date. Transactions in foreign currencies are translated into the Fund's functional currency at exchange rates ruling at the transaction dates. Gains and losses on foreign exchange transactions are recognised in the Profit and Loss Account in determining the result for the period.

At 31 December 2014, in accordance with Financial Reporting Standard 23: The Effects of Changes in Foreign Exchange Rates ("FRS 23"), a year end exchange rate of NOK/USD 0.1334 (31 December 2013: NOK/USD 0.1648) was used to translate the Balance Sheet of Sector Sigma Nordic Fund in arriving at the total USD value for the Company in the financial statements.

At 31 December 2014, the Profit and Loss Account and Statement of Changes in Net Assets attributable to holders of Redeemable Participating Shares of Sector Sigma Nordic Fund have been prepared using an average rate of exchange of NOK/USD 0.1591 (31 December 2014: NOK/USD 0.1701) in arriving at the total USD value for the Company in the financial statements. This results in a foreign currency translation loss in the Statement of Changes in Net Assets attributable to holders of Redeemable Participating Shares when compared to the NOK/USD rate used at year end. The adjustment recorded in the Statement of Changes in Net Assets attributable to holders of Redeemable Participating Shares for the year ended 31 December 2014 was a loss of USD9,567,442 (31 December 2013: loss USD2,401,693).

#### (f) Offsetting financial instruments

Financial assets and financial liabilities maybe offset and the net amount reported in the Balance Sheet when there is a legally enforceable right to offset the recognised amounts and there is an intention to settle on a net basis, or realise the asset and settle the liability simultaneously. As at 31 December 2014 and 31 December 2013 no offsetting has been presented.

#### (g) Income

Dividends are recognised as income on the dates that securities are first quoted "ex-dividend" to the extent information thereon is reasonably available to the Company. Interest income is accrued on a daily basis. Deposit interest is recognised as income on an accruals basis.

#### (h) Expenses

Operating expenses are accounted for on an accruals basis.

#### (i) Net asset value per share

The Net Asset Value per Share of each class is calculated by dividing the Net Asset Value attributable to a class by the number of shares of a class in issue as at the relevant valuation point.

#### (j) Redeemable participating shares

Redeemable participating shares are redeemable at the shareholders opinion and are classified as a financial liability.

#### (k) Amounts due from/to broker

Amounts due from/to broker relate to the outstanding amounts pending settlement on forward foreign currency contracts.

#### (l) Taxation

The Company incurs dividend withholding tax imposed by certain countries on investment income. Dividend income is shown gross of any non-recoverable withholding taxes, which are disclosed separately in Profit and Loss Account.

Annual Report and Audited Financial Statements For the year ended 31 December 2014

## NOTES TO THE FINANCIAL STATEMENTS (Continued)

#### 2. Summary of Significant Accounting Policies (Continued)

#### (m) Transaction costs

Transaction costs are costs incurred to acquire financial assets or financial liabilities at fair value through profit or loss. They include fees and commissions paid to agents, advisers, brokers and dealers. Transaction costs, when incurred, are immediately recognised in profit or loss as an expense. For the period ended 31 December 2014 Sector Global Equity Kernel Fund incurred transaction costs of USD97,262, Sector Healthcare Value Fund incurred transaction costs of USD76,182 (31 December 2013: USD66,327) and Sector Sigma Nordic incurred transaction costs of NOK1,594,898 (31 December 2013: NOK757,682).

#### 3. Dividend and Distribution Policy

The Directors do not currently intend to pay dividends. Accordingly, the price of the shares shall rise as income and capital gains accrue.

#### 4. Taxation

The Company will not be liable to tax in respect of its income and gains, other than on the occurrence of a chargeable event. Generally a chargeable event arises on any distribution, redemption, repurchase, cancellation, transfer of shares or on the ending of a 'Relevant Period', a 'Relevant Period' being an eight year period beginning with the acquisition of the shares by the shareholders and each subsequent period of eight years beginning immediately after the preceding relevant period.

A chargeable event does not include:

- (i) Any transactions in relation to shares held in a recognised clearing system: or
- (ii) An exchange of shares representing a fund for another fund: or
- (iii) An exchange of shares arising on a qualifying amalgamation or reconstruction of a Fund with another fund: or
- (iv) Certain exchanges of shares between spouses and former spouses.

A chargeable event will not occur in respect of shareholders who are neither resident nor ordinarily resident in Ireland and who have provided the Company with a relevant declaration to that effect.

In the absence of an appropriate declaration, the Company will be liable to Irish Tax on the occurrence of a chargeable event. There were no chargeable events during the year under review. Capital gains, dividends and interest received may be subject to withholding taxes imposed by the country of origin and such taxes may not be recoverable by the Company or its shareholders.

#### 5. Exchange Rates

The following exchange rates (against USD) were used to convert the investments and other assets and liabilities denominated in currencies other than USD as at 31 December 2014 and 31 December 2013:

Currency	<b>31 December 2014</b>	<b>31 December 2013</b>
Australian Dollar	1.2220	n/a
Brazilian Real	2.6582	n/a
British Pound	0.6413	0.6038
Canadian Dollar	1.1583	n/a
Chinese Renminbi	6.2040	n/a
Danish Krone	6.1537	5.4142
Euro	0.8264	0.7257
Hong Kong Dollar	7.7548	n/a
Hungarian Forint	263.1579	217.3913
Japanese Yen	119.8897	105.2632
Norwegian Krone	7.4975	6.0680
Swedish Krona	7.8283	6.4226
Swiss Franc	0.9936	0.8894

Annual Report and Audited Financial Statements For the year ended 31 December 2014

## NOTES TO THE FINANCIAL STATEMENTS (Continued)

#### 5. Exchange Rates (Continued)

The following exchange rates (against NOK) were used to convert the investments and other assets and liabilities denominated in currencies other than NOK as at 31 December 2014 and 31 December 2013:

Currency	<b>31 December 2014</b>	31 December 2013
British Pound	0.0855	0.0995
Danish Krone	0.8207	0.8924
Euro	0.1102	0.1196
Swedish Krona	1.0441	1.0586
US Dollar	0.1334	0.1648

An average exchange rate of 0.1591 was used to convert NOK to USD in the Profit and Loss Account (31 December 2013: 0.1701).

#### 6. Cash

As at 31 December 2014 and 31 December 2013 all cash balances are held with BNY Mellon Trust Company (Ireland) Limited (the "Custodian"), DNB, Goldman Sachs and Nordea.

	Sector Global Equity Kernel Fund USD	Sector Healthcare Value Fund USD	Sector Sigma Nordic Fund NOK
31 December 2014			
BNY Mellon	312,960	4,040,923	37,639,814
DNB	-	-	32,343,434
Goldman Sachs	(71)	-	9,128,070
Nordea	<del>_</del>	-	42,156,423
	312,889	4,040,923	121,267,741
31 December 2013			
BNY Mellon		3,327,064	14,944,691
DNB		-	10,088,681
Goldman Sachs		-	4,584,185
Nordea		-	3,634
	_	3,327,064	29,621,191

## 7. Financial Instruments and Associated Risks

Included in the Company's financial instruments, but not limited to, are global equities and equity related securities (including but not limited to American Depositary Receipts, Global Depositary Receipts, European Depositary Receipts and other equity based derivatives) that shall be listed or traded on any market.

The main risks arising from the Company's financial instruments are market price, liquidity, foreign currency and credit risks.

The Market Risk Group ("MRG") functions across all Sector Investment Manager entities and the group is responsible for defining risk management related limits in addition to the investment restrictions found in the Prospectus and related supplements, securing that the Funds have a portfolio construction and risk exposure that are in line with the intentions of the individual Funds. The limits are generally related to exposure towards single positions and sectors, total portfolio exposure and Value-at-Risk ("VAR"). MRG consists of the CEO of Sector Asset Management AS (leader of MRG), Head of Fund Operations and CEO of Sector Fund Services AS. The Head of Fund Operations has the mandate to give short term exceptions to the risk limits set by MRG if he/she finds that under certain market conditions, the limits have unintended adverse effects, for example in extreme market conditions. Such exceptions are reported to the other members of MRG and to the Group Chief Compliance Officer.

#### (a) Market price risk

Market price risk arises from uncertainty concerning future prices of financial instruments. The consequence might be a decline in the Fund's value. The risk related to the Funds – i.e. a combination of the probability of loss and the consequences – must be weighed against the potential gain for the Fund. To limit the risk, the Funds are both diversified and constructed through fundamental analyses of the expected behaviour and volatility of the individual instruments while following each Fund's investment objective.

Annual Report and Audited Financial Statements For the year ended 31 December 2014

## NOTES TO THE FINANCIAL STATEMENTS (Continued)

#### 7. Financial Instruments and Associated Risks (Continued)

#### (a) Market price risk (Continued)

The main risk management tool for VaR calculations was Bloomberg Alpha. The Bloomberg Alpha VaR calculation is based on Monte Carlo simulations at a 95% confidence interval i.e. that one in every 20 days is expected to be above this measure in the long run. The MRG utilises the commitment approach to calculate global exposure.

There are inherent limitations to VaR. While VaR offers a clear, quantifiable measure, predicting futures behaviour involves extracting patterns from past data and applying judgment and modelling to project forward. There is no guarantee that any particular combination of past data modelling or judgment will actually predict future performance. For the purposes of the figures below, the holding period is 1 day and the length of data history used in the model is one year.

#### For the year ended 31 December 2014

Sector Global Equity Kernel Fund	Year end VaR	Gross Exposure* 99%	Net Exposure** 99%	lowest VaR 0.8%	highest VaR 1.4%	average VaR
Sector Healthcare Value Fund	Year end VaR	Gross Exposure* 99%	Net Exposure** 99%	lowest VaR 0.9%	highest VaR 1.2%	average VaR
Sector Sigma Nordic Fund  * Exposure as % of NAV	Year end VaR 0.5%	Gross Exposure* 95%	Net Exposure** 33%	lowest VaR 0.3%	highest VaR 0.8%	average VaR 0.6%

<sup>\*</sup> Exposure as % of NAV

#### For the year ended 31 December 2013

<sup>\*</sup> Exposure as % of NAV

#### Exposure

Exposure for pure equities is equal to the fair value of the securities. The total gross exposure of each Fund is the sum of the absolute values of all long and short exposures.

#### (b) Interest rate risk

Interest rate risk is the risk (variability in value) borne by an interest-bearing asset, due to variability of interest rates. In general, as rates rise, the price of a fixed rate bond will fall, and vice versa. Interest rate risk is commonly measured by the bond's duration. For the year ended 31 December 2014 and 31 December 2013 the Funds have not invested in interest bearing assets, other than cash amounts. As at 31 December 2014 and 31 December 2013, the Funds do not have any significant fair value interest rate risk exposure.

Tables outlining the currency and interest exposure as at 31 December 2014 and 31 December 2013 are outlined in note 7(d).

<sup>\*\*</sup> Net open position as % of NAV

<sup>\*\*</sup> Net open position as % of NAV

Annual Report and Audited Financial Statements For the year ended 31 December 2014

#### NOTES TO THE FINANCIAL STATEMENTS (Continued)

#### 7. Financial Instruments and Associated Risks (Continued)

#### (c) Liquidity risk

Liquidity risk is linked to the Funds having to realise assets in unfavourable market conditions with large losses as a consequence due to for example, redemptions in a Fund or a collapse in long asset values. This means that there are two aspects that are monitored; what is the probability of the situation occurring and how fast can the Funds realise their positions without significant adverse effects on the value of the positions.

#### Liquidity of portfolio

The Company's prospectus provides for daily subscription and redemption of shares in the Funds, therefore the Funds are exposed to a liquidity risk of meeting shareholder redemptions on a daily basis. The majority of the Funds' assets are comprised of publicly traded securities and are thus relatively easily realised. Still, with each Fund having positions in small cap equities, the ability of a Fund to realise assets within a short period of time without a large negative impact on the value of the assets is important. Some of the recognised exchanges on which a Fund may invest may prove to be less liquid or highly volatile from time to time. The Funds may invest a limited proportion of their assets in unquoted securities.

For the year ended 31 December 2014 and 31 December 2013, the Funds held very liquid assets and liquidity was monitored daily by the Investment Manager.

The reports below are snapshots of the estimated liquidity of the Funds as at 31 December 2014:

#### **Sector Global Equity Kernel Fund**

Description	Cumulative
< 1 day	100%
1-2 days	100%

#### Sector Healthcare Value Fund

Description	Cumulative
< 1 day	96%
1-2 days	100%

#### Sector Sigma Nordic Fund

Description	Cumulative
< 1 day	91%
1-2 days	96%
3-5 days	97%
1-2 weeks	98%
3-4 weeks	99%
> 4 weeks	100%

Annual Report and Audited Financial Statements For the year ended 31 December 2014

#### NOTES TO THE FINANCIAL STATEMENTS (Continued)

#### 7. Financial Instruments and Associated Risks (Continued)

#### (c) Liquidity risk (Continued)

The reports below are snapshots of the estimated liquidity of the Funds as at 31 December 2013:

#### **Sector Healthcare Value Fund**

Description	Cumulative
< 1 day	98.04%
1-2 days	100.00%

#### Sector Sigma Nordic Fund

Description	Cumulative
< 1 day	96.95%
1-2 days	99.17%
3-5 days	100.00%

#### (d) Foreign currency risk

A substantial portion of the financial assets of the Funds are denominated in currencies other than the relevant Fund's functional currency with the effect that the balance sheet of the Funds can be significantly affected by currency movements.

Foreign currency risk is in reality a sub-group of market risk, but with its own idiosyncrasies, both with respect to the Funds portfolio as well as the investor classes denominated in different currencies. Certain currency related transactions may, for example, be employed by the Funds in order to hedge against foreign exchange risk subject to the conditions and limits laid down by the Central Bank of Ireland. Such transactions include forward foreign currency contracts and may for example be executed in cases where an investment is in a currency other than the Fund's functional currency.

#### **Currency exposure for investor classes**

The shares of the Company are denominated in United States Dollars (USD), Euro (EUR) and Norwegian Krone (NOK) and are issued and redeemed in those currencies. The Investment Manager may seek to hedge the foreign currency exposure of the assets attributable to the shares in order to neutralise as far as reasonably possible, the impact of fluctuations in exchange rates. This is done monthly in addition to when a Fund has more than 3% absolute return, month to date. There is no guarantee that such hedging will give returns that are equal regardless of which currency the shareholders have invested in. In addition, shareholders whose assets and liabilities are predominantly in currencies other than the currency of investment in the Company should take into account the potential risk of loss arising from fluctuations in value between USD, EUR or NOK, being the currency of shareholder investment, and such other currencies as invested in by the Company.

#### Portfolio currency exposure

The Funds trade in many different markets across the world and in many different currencies. Thus, certain assets in the portfolio may, regardless of the shares of the Fund, be invested in securities which are denominated in currencies other than USD, EUR or NOK. Consequently, the value of such assets will be affected either favourably or unfavourably by fluctuations in currency rates. The exposure towards the different currencies based on the denomination of the securities is reported daily for each Fund. For each individual Fund, action towards currency exposure in the portfolio is taken by the Investment Manager based on reported exposure of the Fund's assets.

Amounts represented below primarily are monetary assets and monetary liabilities except for investments in non-interest bearing securities, which include equities and contracts-for-difference, which are non-monetary assets.

Annual Report and Audited Financial Statements For the year ended 31 December 2014

## NOTES TO THE FINANCIAL STATEMENTS (Continued)

## 7. Financial Instruments and Associated Risks (Continued)

## (d) Foreign currency risk (Continued)

The foreign currency exposure as at 31 December 2014 is as follows:

	Cash at Bank	Forward Currency	Investments in Interest	Investments in Non-Interest	Investments in Non-Interest	Net Other Assets/	Total Net
Sector Global	and Brokers	Contracts	Bearing Assets	Bearing Assets	Bearing Liabilities	(Liabilities)	Asset Value
Equity Kernel Fund							
Currency	USD	USD	USD	USD	USD	USD	USD
AUD	2,172	_	-	193,671	_	-	195,843
BRL	165	-	_	_	=-	-	165
CAD	2,934	_	-	280,094	_	726	283,754
CHF	2,025	-	-	307,392	_	-	309,417
CNY	=	-	-	24,165	_	-	24,165
DKK	2,837	_	-	_	_	-	2,837
EUR	7,489	_	-	1,002,641	_	-	1,010,130
GBP	4,883	_	-	716,258	_	1,753	722,894
HKD	585	_	-	264,304	_	-	264,889
JPY	154	_	-	1,095,090	_	762	1,096,006
NOK	13,664	_	-	_	_	-	13,664
SEK	109	_	_	_	_	_	109
United States							
Dollar	_	_	-	201,258	_	-	201,258
USD	275,872	_	_	5,796,275	_	(44,753)	6,027,394
Total	312,889	_	_	9,881,148	-	(41,512)	10,152,525

	Cash at Bank	Forward Currency	Investments in Interest	Investments in Non-Interest	Investments in Non-Interest	Net Other Assets/	Total Net
Sector	and Brokers	Contracts	Bearing Assets	Bearing Assets	Bearing Liabilities	(Liabilities)	Asset Value
Healthcare							
Value Fund							
Currency	USD	USD	USD	USD	USD	USD	USD
CHF	449	_	-	1,600,765	_	=	1,601,214
DKK	133	_	=	2,394,637	_	=	2,394,770
EUR	10,413	(99,327)	-	7,471,430	_	=	7,382,516
GBP	113	_	-	3,061,650	_	14,813	3,076,576
HUF	39	-	-	_	_	-	39
JPY	2,225	-	-	5,476,573	_	8,476	5,487,274
NOK	4,104	(176,741)	_	_	_	_	(172,637)
SEK	24	_	_	662,890	_	_	662,914
USD	4,023,423	_	_	37,128,615	_	(2,998,395)	38,153,643
Total	4,040,923	(276,068)	_	57,796,560	_	(2,975,106)	58,586,309

Seaton Sigma	Cash at Bank and Brokers	Forward Currency Contracts	Investments in Interest	Investments in Non-Interest	Investments in Non-Interest	Net Other Assets/ (Liabilities)	Total Net Asset Value
Sector Sigma Nordic Fund	and brokers	Contracts	Bearing Assets	Bearing Assets	Bearing Liabilities	(Liabilities)	Asset value
Currency	NOK	NOK	NOK	NOK	NOK	NOK	NOK
DKK	(4,222)	=	=	35,612,177	(85,118)	=	35,522,837
EUR	65,367	278,847	_	16,877,586	(43,180)	-	17,178,620
GBP	455	· —	_	-	· · · · · · ·	-	455
NOK	120,508,229	10,659	_	70,026,586	(22,589)	(6,158,055)	184,364,830
SEK	533,474		_	90,736,121	` _		91,269,595
USD	164,438	=	_	, , , <sub>=</sub>	=	=	164,438
Total	121,267,741	289,506	_	213,252,470	(150,887)	(6,158,055)	328,500,775

Annual Report and Audited Financial Statements For the year ended 31 December 2014

## NOTES TO THE FINANCIAL STATEMENTS (Continued)

## 7. Financial Instruments and Associated Risks (Continued)

## (d) Foreign currency risk (Continued)

The foreign currency exposure as at 31 December 2013 is as follows:

	Cash at Bank	Forward Currency	Investments in Interest	Investments in Non-Interest	Investments in Non-Interest	Net Other Assets/	Total Net
Sector	and Brokers	Contracts	Bearing Assets	Bearing Assets	Bearing Liabilities	(Liabilities)	Asset Value
Healthcare							
Value Fund							
Currency	USD	USD	USD	USD	USD	USD	USD
CHF	284	-	-	2,356,710	_	_	2,356,994
DKK	358	-	-	2,631,647	_	_	2,632,005
EUR	62,871	(39,631)	-	8,398,336	_	323,070	8,744,646
GBP	9,817	-	-	3,954,649	_	_	3,964,466
HUF	65	-	-	816,171	_	_	816,236
JPY	366	_	=	5,685,809	=	=	5,686,175
NOK	2,859	135,740	-	_	_	117,097	255,696
SEK	49	-	-	1,143,462	_	_	1,143,511
USD	3,250,395	-	_	50,834,054	=	(1,264,743)	52,819,706
Total	3,327,064	96,109	_	75,820,838	_	(824,576)	78,419,435

Sector Sigma Nordic Fund	Cash at Bank and Brokers	Forward Currency Contracts	Investments in Interest Bearing Assets	Investments in Non-Interest Bearing Assets	Investments in Non-Interest Bearing Liabilities	Net Other Assets/ (Liabilities)	Total Net Asset Value
Currency	NOK	NOK	NOK	NOK	NOK	NOK	NOK
DKK	84,110	_	_	27,358,176	(313,053)	_	27,129,233
EUR	63,490	3,033	_	15,212,273	(439,863)	-	14,838,933
GBP	100,874	_	_	_	_	_	100,874
NOK	22,424,388	231,319	_	50,582,600	(143,105)	(8,265,127)	64,830,075
SEK	2,043,164	_	_	81,030,134	(2,861,063)	_	80,212,235
USD	4,905,165	(74,275)	_	5,741,898	(427,657)	107,080	10,252,211
Total	29,621,191	160,077	_	179,925,081	(4,184,741)	(8,158,047)	197,363,561

As at 31 December 2014 the following forward foreign currency contracts were held by the Funds:

Maturity Date	Counterparty	Sale Currency	Amount	Purchase Currency	Amount	Unrealised gain/(loss) USD		
2/2/2015	BNY Mellon	USD	19,937,356	EUR	16,388,709	(99,327)		
2/2/2015	BNY Mellon	USD	18,535,628	NOK	137,774,729	(176,741)		
Total unrealised g	Total unrealised gain on forward foreign currency contracts							

Sector Sigma Nordic Fund									
<b>Maturity Date</b>	Counterparty	Sale Currency	Amount	Purchase Currency	Amount	Unrealised gain/(loss)			
						NOK			
2/2/2015	BNY Mellon	NOK	59,357,891	EUR	6,565,049	278,847			
2/2/2015	BNY Mellon	NOK	1,115,655	USD	150,085	10,659			
Total unrealised g	289,506								

Annual Report and Audited Financial Statements For the year ended 31 December 2014

#### NOTES TO THE FINANCIAL STATEMENTS (Continued)

#### 7. Financial Instruments and Associated Risks (Continued)

#### (d) Foreign currency risk (Continued)

As at 31 December 2013 the following open forward foreign currency contracts were held by the Funds:

#### Sector Healthcare Value Fund

<b>Maturity Date</b>	Counterparty	Sale Currency	Amount	<b>Purchase Currency</b>	Amount	Unrealised gain/(loss)
						USD
2/1/2014	BNY Mellon	USD	433,353	NOK	2,658,232	4,771
3/2/2014	BNY Mellon	USD	18,968,026	EUR	13,736,834	(39,631)
3/2/2014	BNY Mellon	USD	14,534,294	NOK	89,085,672	130,969
Total unrealised g		96,109				

#### Sector Sigma Nordic Fund

<b>Maturity Date</b>	Counterparty	Sale Currency	Amount	Purchase Currency	Amount	Unrealised gain/(loss)
						NOK
2/1/2014	BNY Mellon	NOK	4,941,297	USD	802,172	(74,275)
2/1/2014	BNY Mellon	USD	802,172	NOK	4,911,376	44,353
2/1/2014	BNY Mellon	NOK	16,810,307	EUR	2,011,060	3,033
2/1/2014	BNY Mellon	EUR	2,011,060	NOK	17,000,307	186,966
Total unrealised g	gain on forward forei	gn currency contracts				160,077

#### (e) Credit risk

Credit risk is the risk that a counterparty will fail to discharge an obligation or commitment that is has entered into with the Funds.

The Funds are exposed to credit risk associated with counterparties with whom it trades or hold assets, and will also be exposed to the risk of settlement default. All transactions in listed securities are settled/paid for upon delivery using approved brokers. The risk of default is considered minimal, as delivery of securities sold is only made once the broker has received payment. Payment is made on a purchase once the securities have been received by the broker. The trade will fail if either party fails to meet its obligation.

#### **Trade counterparty**

The Funds mitigate counterparty risk by undertaking transactions with large and well capitalised counterparties. The Funds also seek to trade with more than one counterparty and have reduced the activity with counterparties when there have been questions raised regarding the robustness of counterparties in terms of credit risk.

Although it is the intention of the Investment Managers to follow a general policy of seeking to spread the Funds' capital at risk over a number of investments and counterparties, the Funds may at certain times hold relatively few positions with the result that a loss in any such position either to trading counterparty or settlement default could have a substantial adverse impact on a Fund's capital.

The table below shows the long-term S&P credit ratings for the counterparties that hold cash as at 31 December 2014 and 31 December 2013:

	31 December 2014	31 December 2013
BNY Mellon	A+	A+
DNB	A+	A+
Goldman Sachs International	A	A-
Nordea Bank	AA-	AA-

The value of underlying securities, held by Sector Sigma Nordic Fund, pledged as collateral with Goldman Sachs, in relation to derivative contracts-for-difference trading as at 31 December 2014 was as follows:

Annual Report and Audited Financial Statements For the year ended 31 December 2014

# NOTES TO THE FINANCIAL STATEMENTS (Continued)

#### 7. Financial Instruments and Associated Risks (Continued)

#### (e) Credit risk (Continued)

Sector Sigma Nordic Fund

		Market Value of
Security	Counterparty	Margin
		NOK
AarhusKarlshamn AB	Goldman Sachs	5,862,543
Royal UNIBREW A/S	Goldman Sachs	8,068,435

#### (f) Fair value estimation

Investments measured and reported at fair value are classified and disclosed in one of the following fair value hierarchy levels based on the significance of the inputs used in measuring its fair value:

Level 1 inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the valuation date. An active market for the asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.

Level 2 inputs are inputs, other than quoted prices in active markets included within level 1 that are observable for the asset or liability, either directly or indirectly. Fair value is determined through the use of models or other valuation methodologies. Level 2 inputs include the following:

- a. Quoted prices for similar assets or liabilities in active markets.
- b. Quoted prices for identical or similar assets or liabilities in markets that are not active, that is, markets in which there are few transactions for the asset or liability, the prices are not current, or price quotations vary substantially either over time or among market makers, or in which little information is released publicly.
- c. Inputs other than quoted prices that are observable for the asset or liability (e.g. interest rate and yield curves observable at commonly quoted intervals, volatilities, prepayment speeds, loss severities, credit risks and default rates).
- d. Inputs that are derived principally from or corroborated by observable market data by correlation or other means.

Level 3 inputs are unobservable inputs for the asset or liability. Unobservable inputs reflect the Company's own assumptions about how market participants would be expected to value the asset or liability. Unobservable inputs are developed based on the best information available in the circumstances, other than market data obtained from sources independent of the Company and might include the Company's own data.

An investment is always categorised as level 1, 2 or 3 in its entirety. In certain cases, the fair value measurement for an investment may use a number of different inputs that fall into different levels of the fair value hierarchy. In such cases, an investment's level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. The assessment of the significance of a particular input to the fair value measurement requires judgment and is specific to the investment.

The fair values of investments valued under levels 1 to 3 are as follows for the year ended 31 December 2014:

Sector Global Equity Kernel Fund	Level 1 USD	Level 2 USD	Level 3 USD	31 December 2014 USD
Financial assets at fair value through profit or loss				
Equity securities	9,856,983	_	_	9,856,983
Derivative instruments	_	24,165	_	24,165
Total	9,856,983	24,165		9,881,148

Annual Report and Audited Financial Statements For the year ended 31 December 2014

# NOTES TO THE FINANCIAL STATEMENTS (Continued)

# 7. Financial Instruments and Associated Risks (Continued)

# (f) Fair value estimation (Continued)

				31 December
Sector Healthcare Value Fund	Level 1	Level 2	Level 3	2014
	USD	USD	USD	USD
Financial assets at fair value through profit or loss				
Equity securities	57,796,560	_	_	57,796,560
Financial liabilities at fair value through profit or loss				
Derivative instruments	_	(276,068)	_	(276,068)
Total	57,796,560	(276,068)	_	57,520,492
				31 December
Sector Sigma Nordic Fund	Level 1	Level 2	Level 3	2014
~~····	NOK	NOK	NOK	NOK
Financial assets at fair value through profit or loss				
Equity securities	210,955,683	_	_	210,955,683
Derivative instruments	588,382	1,997,911	-	2,586,293
Financial liabilities at fair value through profit or loss				
Derivative instruments	_	(150,887)	_	(150,887)
Total	211,544,065	1.847.024	_	213,391,089

The categories of investments above comprise:

- Equity securities (which include equities and contracts-for-difference) and
- •Derivative instruments (which includes forward foreign currency contracts and options).

There were no significant transfers between levels for the year ended 31 December 2014.

The fair values of investments valued under levels 1 to 3 are as follows for the period ended 31 December 2013:

				31 December
Sector Healthcare Value Fund	Level 1	Level 2	Level 3	2013
	USD	USD	USD	USD
Financial assets at fair value through profit or loss				
Equity securities	75,820,838	_	_	75,820,838
Derivative instruments	_	135,740	-	135,740
Financial liabilities at fair value through profit or loss				
Derivative instruments	_	(39,631)	_	(39,631)
Total	75,820,838	96,109	_	75,916,947
				,
				31 December
Sector Sigma Nordic Fund	Level 1	Level 2	Level 3	31 December 2013
Sector Sigma Nordic Fund	Level 1 NOK	Level 2 NOK	Level 3 NOK	
Sector Sigma Nordic Fund  Financial assets at fair value through profit or loss				2013
				2013
Financial assets at fair value through profit or loss	NOK			2013 NOK
Financial assets at fair value through profit or loss Equity securities	NOK 178,500,269	NOK –		2013 NOK 178,500,269
Financial assets at fair value through profit or loss Equity securities Derivative instruments	NOK 178,500,269	NOK –		2013 NOK 178,500,269
Financial assets at fair value through profit or loss Equity securities Derivative instruments  Financial liabilities at fair value through profit or loss	NOK 178,500,269	NOK - 1,611,934		2013 NOK 178,500,269 1,659,164

There were no significant transfers between levels for the year ended 31 December 2013.

Annual Report and Audited Financial Statements For the year ended 31 December 2014

### NOTES TO THE FINANCIAL STATEMENTS (Continued)

#### 8. Share Capital

The authorised share capital of the Company is 1,000,000,000,000,000 Shares of no par value initially designated as unclassified shares. The issued share capital of the Company is  $\bigcirc$  represented by 2 shares (the "Subscriber Shares") issued for the purposes of the incorporation of the Company at an issue price of  $\bigcirc$  per Share which are fully paid up and which are beneficially owned by Sector Asset Management AS and Sector Fund Services AS.

Sector Global Equity Kernel Fund may issue Class A EUR Shares, Class A NOK Shares, Class A SEK Shares and Class A USD Shares (the "Class A Shares"), Class B EUR Shares, Class B NOK Shares, Class B SEK Shares and Class B USD Shares (the "Class B Shares"), Class C EUR Shares, Class C NOK Shares, Class C SEK Shares and Class C USD Shares (the "Class C Shares"), Class L NOK Shares, Class O NOK Shares, and Class P NOK Shares and Class P USD Shares ("the Class P Shares").

Sector Healthcare Value Fund may issue Class A EUR Shares, Class A NOK Shares, Class A SEK Shares and Class A USD Shares (the "Class A Shares"), Class B EUR Shares, Class B NOK Shares, Class B SEK Shares and Class B USD Shares (the "Class B Shares") and Class L NOK Shares.

Sector Sigma Nordic Fund may issue Class A EUR Shares, Class A NOK Shares, Class A SEK Shares and Class A USD Shares (the "Class A Shares"), Class B EUR Shares, Class B NOK Shares, Class B SEK Shares and Class B USD Shares (the "Class B Shares"), Class C NOK Shares and Class C SEK Shares (the "Class C Shares") and Class L NOK Shares.

On a show of hands every holder who is present in person or by proxy shall have one vote and the holders of Subscriber Shares present or in person or by proxy shall have one vote.

The rights attached to any class may, be varied or abrogated with the consent in writing of the holders of three-fourths in number of the issued Shares of that class, or with the sanction of a special resolution passed at a separate general meeting of the holders of the Shares of the class, and may be so varied or abrogated either whilst the Company is a going concern or during or in contemplation of a winding-up. The quorum at any such separate general meeting, other than an adjourned meeting, shall be two persons holding or representing by proxy at least one third of the issued Shares of the class in question and the quorum at an adjourned meeting shall be one person holding Shares of the class in question or his proxy.

Class L NOK Shares and Class O NOK (issued by Sector Global Equity Kernel Fund) are only available for subscription by (i) other funds, (including sub-funds of the Company), or similar collective investment schemes that a Sector Group (as defined in the Company's prospectus) company manages; (ii) the Directors; (iii) any person or investor connected with any such person or entity referred to in parts (i) and (ii) including, without limitation, a trustee of a trust established by or for such an entity, (iv) any company, partnership or other entity controlled by a Sector Group company (v) any company, partnership or other entity which has been appointed or acts as investment manager or investment adviser of an entity referred to in part (i), (vi) any employee of the Sector Group or (vii) any nominee of any of the foregoing.

The Class L NOK Shares (issued by Sector Healthcare Value Fund and Sector Sigma Nordic Fund) are open for public participation. However, the Investment Manager intends the Class L NOK Shares will be primarily invested in by any employees of a Sector Group company, any spouse of such employee, or any company controlled by (one or more) such employee or spouse.

Class L NOK Shares (issued by all Funds) are exempt from paying investment management fees.

The following are the share class transactions during the year ended 31 December 2014:

	Sector Global Equity Kernel Fund	Sector Healthcare Value Fund	Sector Sigma Nordic Fund
Class A EUR			
Shares in issue at beginning of year	-	98,930	-
Number of shares issued	-	70,207	62,766
Number of shares redeemed	-	(71,289)	(15,645)
Number in issue at end of year		97,848	47,121
Class A NOK			
Shares in issue at beginning of year	_	15,692	42,745
Number of shares issued	-	_	31,358
Number of shares redeemed	-	-	_
Number in issue at end of year		15,692	74,103

Annual Report and Audited Financial Statements For the year ended 31 December 2014

# NOTES TO THE FINANCIAL STATEMENTS (Continued)

# 8. Share Capital (Continued)

	Sector Global Equity Kernel Fund	Sector Healthcare Value Fund	Sector Sigma Nordic Fund
Class A USD			
Shares in issue at beginning of year	_	223,138	_
Number of shares issued	=	33,196	9,600
Number of shares redeemed		(171,264)	(8,245)
Number in issue at end of year		85,070	1,355
Class B EUR			
Shares in issue at beginning of year	=	=	16,805
Number of shares issued	_	_	1,388
Number of shares redeemed		=	(7,777)
Number in issue at end of year		_	10,416
Class B NOK			
Shares in issue at beginning of year	_	64,332	91,523
Number of shares issued	_	59,086	16,197
Number of shares redeemed		(27,324)	(19,419)
Number in issue at end of year		96,094	88,301
Class B USD			
Shares in issue at beginning of year	_	_	6,454
Number of shares issued	_	_	1,343
Number of shares redeemed		=	(7,797)
Number in issue at end of year		_	
Class C NOK			
Shares in issue at beginning of year	_	_	2,071
Number of shares issued	_	-	1,583
Number of shares redeemed			(1,156)
Number in issue at end of year		<del>-</del>	2,498
Class L NOK			
Shares in issue at beginning of year	_	25,492	5,936
Number of shares issued	4,000	=	14,248
Number of shares redeemed			20.104
Number in issue at end of year	4,000	25,492	20,184
Class O NOK			
Shares in issue at beginning of year	_	_	-
Number of shares issued	28,791	=	_
Number of shares redeemed	(27,168)	_	
Number in issue at end of year	1,623	=	
Class P USD			
Shares in issue at beginning of year	_	_	_
Number of shares issued	90,075	_	_
Number of shares redeemed	-	_	
Number in issue at end of year	90,075		_

The following are the share class transactions during the year ended 31 December 2013:

	Sector Healthcare Sector S	Sector Healthcare Sector Sigma Nordi	
	Value Fund	Fund	
Class A EUR			
Shares in issue at beginning of year	58,207	_	
Number of shares issued	63,305	_	
Number of shares redeemed	(22,582)	-	
Number in issue at end of year	98,930	_	

Annual Report and Audited Financial Statements For the year ended 31 December 2014

# NOTES TO THE FINANCIAL STATEMENTS (Continued)

#### 8. Share Capital (Continued)

	Sector Healthcare Sector Value Fund	Sigma Nordic Fund
Class A NOK		
Shares in issue at beginning of year	15,692	42,745
Number of shares issued	_	_
Number of shares redeemed  Number in issue at end of year	15,692	42.745
Number in issue at end of year	13,072	72,773
Class A USD		
Shares in issue at beginning of year	139,179	_
Number of shares issued	126,149	_
Number of shares redeemed	(42,190)	
Number in issue at end of year	223,138	
Class B EUR		
Shares in issue at beginning of year	_	10,641
Number of shares issued	_	7,146
Number of shares redeemed	=	(982)
Number in issue at end of year	_	16,805
Class B NOK		
Shares in issue at beginning of year	_	90,711
Number of shares issued	68,921	21,318
Number of shares redeemed	(4,589)	(20,506)
Number in issue at end of year	64,332	91,523
or		
Class B USD		10
Shares in issue at beginning of year Number of shares issued	=	10 6,444
Number of shares redeemed	_	0,444
Number in issue at end of year		6.454
Number in issue at end of year		0,434
Class C NOK		
Shares in issue at beginning of year	_	150
Number of shares issued	_	2,271
Number of shares redeemed		(350)
Number in issue at end of year		2,071
Class L NOK		
Shares in issue at beginning of year	36,139	500
Number of shares issued	_	5,436
Number of shares redeemed	(10,647)	
Number in issue at end of year	25,492	5,936

### 9. Investment Management Fees

The Company has appointed Sector Omega AS as Investment Manager to Sector Global Equity Kernel Fund, Sector Gamma AS as Investment Manager to Sector Healthcare Value Fund and has appointed Sigma Fondsforvaltning AS as Investment Manager to Sector Sigma Nordic Fund to provide investment management services pursuant to the investment management agreement between the Company and the Investment Manager.

Sector Global Equity Kernel Fund pays the Investment Manager a management fee of up to 1.5 per cent per annum of the Net Asset Value of the Class A Shares, up to 0.75 per cent per annum of the Net Asset Value of the Class B Shares, up to 0.5 per cent per annum of the Net Asset Value of the Class C Shares, up to 0.3 per cent per annum of the Net Asset Value of the Class P Shares and up to 3.0 per cent per annum of the Net Asset Value of the Class O Shares. The Investment Manager does not charge a fee in respect of the Class L NOK Shares.

Sector Healthcare Value Fund pays the Investment Manager a management fee of 1 per cent per annum of the Net Asset Value of Class A Shares and 2 per cent per annum of the Net Asset Value of Class B Shares. The Investment Manager does not charge a fee in respect of the Class L NOK Shares.

Sector Sigma Nordic Fund pays the Investment Manager a management fee of 1 per cent per annum of the Net Asset Value of Class A Shares, 1.5 per cent per annum of the Net Asset Value of Class B Shares, and 2 per cent per annum of the Net Asset Value of Class C Shares. The Investment Manager will not charge a fee in respect of Class L NOK Shares.

Annual Report and Audited Financial Statements For the year ended 31 December 2014

### NOTES TO THE FINANCIAL STATEMENTS (Continued)

#### 9. Investment Management Fees (Continued)

The management fees accrued for the year ended 31 December 2014 were USD1,364,900 (31 December 2013: USD857,507) and the amount outstanding at 31 December 2014 was USD117,509 (31 December 2013: USD94,279).

The Investment Manager to Sector Global Equity Kernel Fund does not anticipate that the "Total Expense Ratio" which includes but is not limited to the management fee, administrator fees and expenses, custodian fees and expenses, establishment costs of the Fund and other operating expenses of the Fund will exceed 0.5% of the Net Asset Value of Class P USD Shares each year of the Fund's operation (the "TER Threshold"). If the Total Expense Ratio exceeds the TER Threshold, the Investment Manager has undertaken to discharge that proportion of the Total Expense Ratio of Class P USD Shares above the TER Threshold and shall rebate the Fund accordingly.

The Investment Manager will invest in Class O NOK Shares in Sector Global Equity Kernel Fund and beginning on the date the Class O NOK subscription is booked to the Fund, the aggregate fees for Class P USD above the Class P USD threshold will be funded in this order on an ongoing basis; i) by utilising the 3% management fee attributable to Class O NOK, then ii) by utilising any preliminary charges attributable to Class O NOK accrued on the Fund. If the amounts funded in accordance with (i) and (ii) are not sufficient to achieve the Class P USD TER Threshold, then this excess cost shall accrue and be offset against future fees attributable to the Investment Manager, including future preliminary charges attributable to future investments in Class O NOK.

The total fees waived by the Investment Manager for the year ended 31 December 2014 was USD106,086 (31 December 2013: USDnil) and the amount outstanding at 31 December 2014 was USD8,953 (31 December 2013: USDnil).

#### 10. Incentive Fees

The Investment Manager is also entitled to receive an incentive fee, as calculated on the following basis:

#### Sector Global Equity Kernel Fund

The Fund, in respect of the Class B Shares, Class C Shares and Class O NOK Shares pays the Investment Manager an incentive fee (the "Incentive Fee") equal to 10 per cent of the amount by which the Net Asset Value (before the deduction of any performance fee) of the relevant Class exceeds the MSCI ACWI Index ("Index") adjusted Prior High Net Asset Value ("Index adjusted Prior High Net Asset Value") (as defined below). No Incentive Fee is charged in respect of the Class A Shares, Class P Shares and Class L NOK Shares.

The Incentive Fee is calculated on a share-by-share basis so that each share is charged a fee which equates precisely with that share's performance over each Calculation Period (as defined below). This method of calculation ensures that (i) any Incentive Fee paid to the Investment Manager is charged only to those shares which have outperformed their respective Prior High Net Asset Value over the course of a Calculation Period, (ii) all holders of shares have the same amount of capital per share at risk in the Fund, and (iii) all shares in a particular class have the same net asset value per share.

The Incentive Fee shall only be payable on the amount by which each share outperforms the previous high watermark or Index adjusted Prior High net asset value for the relevant share. For each Calculation Period, an Incentive Fee will only be payable by a particular share if the net asset value of that share at the end of a Calculation Period is greater than the prevailing Prior High Net Asset Value for that share.

The "Prior High Net Asset Value" of each share is the highest net asset value per share on which Incentive Fee was paid in respect of any previous Calculation Period (or, if no Incentive Fee has yet been paid with respect to any such Calculation Period, the Initial Issue Price of the relevant share). The "Index adjusted Prior High Net Asset Value" of each share is the Prior High Net Asset Value adjusted by the performance of the Index for the relevant Calculation Period.

The calculation period for the Incentive Fee shall be a calendar year, closing on the 31 December each year (or if the 31 December is not a Business Day, on the last Business Day of the year) (the "Calculation Period"). The first Calculation Period shall be the period from the close of the initial offer period until the 31 December 2014. Thereafter, the Incentive Fee will be calculated on an annual basis. The Incentive Fee will accrue as at each valuation point and shall be payable annually in arrears (on or after the first business day of the following year).

At the end of each Calculation Period, where an Incentive Fee has been paid, and only then, the Prior High Net Asset Value per share will be reset to the Net Asset Value per share of the relevant class at the end of such Calculation Period. For the avoidance of doubt, where the relevant class has underperformed, (i.e. its net asset value per share at the end of a Calculation Period is below the Index adjusted Prior High Net Asset Value per share), no Incentive Fee will be payable until the underperformance is clawed back.

The Incentive Fee will be verified by the Custodian.

As the Incentive Fee is based on net realised and net unrealised gains and losses as at the end of each Calculation Period and as a result, it may be paid on unrealised gains which may subsequently never be realised.

Annual Report and Audited Financial Statements For the year ended 31 December 2014

### NOTES TO THE FINANCIAL STATEMENTS (Continued)

10. Incentive Fees (Continued) Sector Healthcare Value Fund

The Fund, in respect of the Class A Shares, pays the Investment Manager a fee equal to 20 per cent of the amount by which the net asset value (before the deduction of any performance fee) of the relevant share exceeds the MSCI Daily TR World Net Healthcare USD (the "Index") (the "Incentive Fee"). The relevant share's subscription price or the initial issue price (where shares are issued during the initial offer period) is taken as the starting price for the purposes of determining the Incentive Fee. The Incentive Fee is accrued on a daily basis and reflected in the net asset value per share at each valuation point. The accrued Incentive Fee will only be paid to the Investment Manager once a shareholder redeems its investment in the Fund or when the Fund closes down where the performance of the relevant shares has exceeded the performance of the Index. The Incentive Fee may be payable even if the absolute return on the shareholder's investment is zero or negative. For example, if during the period of a shareholder's investment in the Fund, the net asset value per share on redemption is less than or equal to the net asset value per share that that shareholder paid on its initial subscription into the Fund, the Incentive Fee may still be payable if the net asset value per share on redemption exceeds the Index Net Asset Value per share, i.e. the Fund has outperformed the Index for the period of the shareholder's investment.

The Incentive Fee will be verified by the Custodian.

No Incentive Fee will be charged in respect of the Class B Shares and Class L NOK Shares.

#### Sector Sigma Nordic Fund

The Investment Manager is also entitled to receive an incentive fee (the "Incentive Fee") of the aggregate appreciation in value of the Class A Shares, the Class B Shares and the Class C Shares (each a "Class") during the relevant Calculation Period (as defined below). No Incentive Fee will be charged in respect of the Class L NOK Shares.

The Incentive Fee equals 15% of the aggregate appreciation in value of the Class A Shares and 20% of the aggregate appreciation in value of the Class B Shares and the Class C Shares.

The Incentive Fee accrues as at each valuation point and is calculated annually on the rate of return (net of the Investment Manager's fees) of each class, and will be payable annually in arrears (on or after the first business day of the following year), or upon redemption, if earlier. The calculation period shall be a calendar year, closing on the last business day each year (the "Calculation Period"). The first Calculation Period in respect of Class A USD Shares, Class A EUR Shares, Class A SEK Shares, Class B SEK Shares and Class C SEK Shares will be from the close of the Initial Offer Period until the last business day of 2013. The Incentive Fee will be verified by the Custodian.

The Incentive Fee is calculated on a share-by-share basis so that each share is charged a fee which equates precisely with that share's performance over each Calculation Period. This method of calculation ensures that (i) any Incentive Fee paid to the Investment Manager is charged only to those shares which have outperformed their respective Prior High Net Asset Value (as defined below) over the course of a Calculation Period, (ii) all holders of shares have the same amount of capital per share at risk in the Fund, and (iii) all shares in a particular Class have the same net asset Value per share.

The Incentive Fee shall only be payable on the amount by which each share outperforms the previous high watermark or "Prior High Net Asset Value" (as defined below) for the relevant share. For each Calculation Period, an Incentive Fee will only be payable by a particular share if the net asset value of that share at the end of a Calculation Period is greater than the prevailing Prior High Net Asset Value for that share.

The "Prior High Net Asset Value" of each share is the highest net asset value per share on which Incentive Fee was paid in respect of any previous Calculation Period (or, if no Incentive Fee has yet been paid with respect to any such Calculation Period, the initial issue price of the relevant share). As the Incentive Fee is based on net realised and net unrealised gains and losses as at the end of each Calculation Period and as a result, it may be paid on unrealised gains which may subsequently never be realised.

At the end of each Calculation Period, where Incentive Fee has been paid, and only then, the Prior High Net Asset Value per share will be reset to the net asset value per share of the relevant class at the end of such Calculation Period. For the avoidance of doubt, where the relevant class has underperformed, (i.e. its net asset value per share at the end of a Calculation Period is below the Prior High Net Asset Value per share), no Incentive Fee will be payable until the underperformance is clawed back.

#### **Equalisation Credit**

The equalisation credit policy is applied to the calculation of the Incentive Fee payable by all Funds. The Incentive Fee is calculated on a share-by-share basis so that each relevant share is charged an Incentive Fee that equates precisely with that relevant share's performance. This method of calculation ensures that (i) the Incentive Fee is charged only to those relevant shares that have appreciated in value relative to the Index, (ii) all relevant shareholders have the same amount per relevant share of the relevant class at risk in the Fund, and (iii) all shares of the same class have the same net asset value per share. If a shareholder subscribes for relevant shares at a time when the net asset value per relevant share is other than the Index Net Asset Value, certain adjustments will be made to reduce inequities that could otherwise result to the subscriber or beneficiary of the Incentive Fee.

Annual Report and Audited Financial Statements For the year ended 31 December 2014

# NOTES TO THE FINANCIAL STATEMENTS (Continued)

#### 10. Incentive Fees (Continued)

The Incentive Fees accrued for the year ended 31 December 2014 were USD1,388,156 (31 December 2013: USD1,222,362) and the amount outstanding at 31 December 2014 was USD1,356,740 (31 December 2013: USD1,154,306).

As at 31 December 2014 an equalisation credit of USD559,964 (31 December 2013: USD1,272,720) was applied.

#### 11. Administration Fees and Custodian Fees

The Company has appointed BNY Mellon Investment Servicing (International) Limited ("BNY Mellon") to act as Administrator, registrar and transfer agent and BNY Mellon Trust Company (Ireland) Limited to act as Custodian (the "Custodian"). BNY Mellon is entitled to receive out of the assets of the Funds an annual administration fee, accrued and calculated on each dealing day and payable monthly in arrears of up to 0.105% of the aggregated Net Assets. BNY Mellon is also entitled to a shareholding services fee of USD1,875 per share class per month together with agree upon transaction charges. The Administrator is also entitled a financial reporting fee of up to USD5,000 per set of financial statements and other out of pocket expenses out of the assets of the Funds (plus VAT thereon if any).

The Administration fee accrued for the year ended 31 December 2014 was USD390,816 (31 December 2013: USD263,142) and the amount outstanding at 31 December 2014 was USD86,175 (31 December 2013: USD63,797).

The Custodian is entitled to an asset based fee of up to 0.02% per annum payable monthly together with sub-custodian's fees (which will be charged at normal commercial rates) as well as agreed upon transaction charges (which will be at normal commercial rates) and other out of pocket expenses (plus VAT thereon if any).

The Custodian fee accrued for the year ended 31 December 2014 was USD100,358 (31 December 2013: USD62,817) and the amount outstanding at 31 December 2014 was USD28,510 (31 December 2013: USD9,688).

#### 12. Directors' fees and expenses

The Directors are entitled to a fee in remuneration for their services at a rate to be determined from time to time by the Directors, but so that the aggregate amount of Directors' remuneration in any one year shall not exceed €20,000 or such higher amount as may be approved by resolution of the Directors and notified to Shareholders. The Directors may also be paid all travelling, hotel and other expenses, properly incurred by them, in attending and returning from meetings of the Directors or general meetings of the Company or in connection with the business of the Company.

The Directors' fees and expenses accrued for the year ended 31 December 2014 was USD26,550 (31 December 2013: USD26,776) and the amount outstanding at 31 December 2014 was USD6,600 (31 December 2013: USDnil).

### 13. Auditors' Fees

Fees and expenses paid to the statutory auditors, Deloitte & Touche, in respect of the financial period, entirely relate to the audit of the financial statements of the Company. There were no fees and expenses paid in respect of other assurance, tax advisory or non-audit services provided by the auditors for the year ended 31 December 2013.

Independent auditors' fees charged for the year ending 31 December 2014 were EUR26,625 ex VAT (31 December 2013: EUR35,000).

# 14. Efficient Portfolio Management

The Company may enter into a variety of derivative instruments including, but not limited to, forward foreign exchange contracts, futures, options, swaps, contracts-for-difference, stocklending and repurchase agreements for the purposes of efficient portfolio management only, subject to the conditions and limits set out in the Central Bank of Ireland's Notices and within any further limits laid down by the Central Bank of Ireland from time to time. In particular, the Funds may engage in forward foreign exchange contracts to provide protection against exchange rate risks, including cross-currency hedging, and in order to hedge foreign currency exposure of the underlying assets of the Funds into the base currency of the Funds or into a currency institutionally linked to the base currency. It is intended that the use of such forwards may reduce the currency risk in respect of the Funds and will better enable the Funds to manage its assets and liabilities. Futures contracts may be used to hedge or gain exposure to an increase in the value of an asset, market, currency, or deposit. Options may be used to hedge or achieve exposure to a particular market instead of using a physical security. Swaps may be used to achieve profit as well as to hedge existing long positions. Contracts-for-difference ("CFDs") are bilateral agreements to exchange the difference between opening and closing contracts, which represent the performance of an underlying share.

At the discretion of the Directors, the Funds may use financial derivative instruments as a primary investment policy and details of the investment policy will be set out in the applicable Supplement in accordance with the requirements of the Central Bank of Ireland.

For the year ended 31 December 2014 and 31 December 2013, the Company has utilised forward foreign currency contracts, contracts-for-difference and options.

Annual Report and Audited Financial Statements For the year ended 31 December 2014

# NOTES TO THE FINANCIAL STATEMENTS (Continued)

#### 15. Related Party Transactions

Fees payable to the relevant Investment Manager are disclosed in note 9 and 10.

#### Custodian and Administrator

Although not deemed to be related parties under Irish GAAP as they do not exercise "significant influence" over the activities of the Company, UCITS Notice 14 also deems a "Custodian" and its "associated or group companies" to be 'connected parties" to the Company. As such, BNY Mellon Trust Company (Ireland) Limited, the Custodian, and BNY Mellon Investment Servicing (International) Limited, the Administrator, are connected parties to the Company.

The board of directors are satisfied that there are arrangements (evidenced by written procedures) in place, to ensure that any transaction carried out with the Company by a promoter, manager, custodian, investment manager and/or associated or group companies of these ("connected parties") are carried out as if negotiated at arm's length and that all such transactions are carried out in the best interests of the shareholders. The board of directors are satisfied that transactions with connected parties entered into during the period complied with the obligations set out in Notice UCITS 14.

As at 31 December 2014, Sector Asset Management AS, ultimate parent company of the Investment Manager, held 3 Class A EUR Shares, 2 Class A NOK Shares and 3 Class A USD Shares in Sector Healthcare Value Fund.

As at 31 December 2013, Sector Asset Management AS, ultimate parent company of the Investment Manager, held 3 Class A EUR Shares, 2 Class A NOK Shares and 3 Class A USD Shares in Sector Healthcare Value Fund.

As at 31 December 2014 the following key personnel as defined within FRS 8 "Related party disclosures" held a beneficial interest in the Funds as follows:

			Number of
Key personnel	Role/Team	Fund/Class	Shares held
Sector Omega AS	Investment Manager	Sector Global Equity Kernel Fund, Class O NOK	1,623
Sector Speculare AS	100% owned by Sector Omega AS	Sector Global Equity Kernel Fund, Class L NOK	4,000
Trond Horneland	Investment Manager, Sector Gamma AS	Sector Healthcare Value Fund, Class L NOK	15,665
Trond Tviberg	Investment Manager, Sector Gamma AS	Sector Healthcare Value Fund, Class L NOK	7,945
Jan Henrik Arvesen	Investment Manager, Sigma Fondsforvaltning AS	Sector Sigma Nordic Fund, Class L NOK	3341

The Board of Directors of the Manager is not aware of any transactions with connected persons during the year ended 31 December 2014 other than those disclosed in these financial statements.

#### 16. Contingent Liabilities

The Company is established as a segregated portfolio company. As a matter of Irish law, the assets of one Fund will not be available to satisfy the liabilities of another. However, the Company is a single legal entity which may operate or have assets held on its behalf or be subject to claims in other jurisdictions which may not necessarily recognise such segregation. There is no guarantee that the courts of any jurisdiction outside Ireland will respect the limitations on liability associated with segregated portfolio companies nor is there any guarantee that the creditors of one Fund will not seek to enforce such Funds' obligations against another Fund.

As at 31 December 2014 there were three Funds in operation (31 December 2013: two) and there were no known contingent liabilities.

#### 17. Soft Commission

There were no soft commissions for the years ended 31 December 2014 or 31 December 2013.

#### 18. Prospectus

Revised Supplements for Sector Sigma Nordic Fund were issued on 24 January 2014 and 12 December 2014.

Revised Supplements for Sector Global Equity Kernel Fund were issued on 28 April 2014 to include Class O NOK Shares, 5 November 2014 and 12 December 2014.

A revised Supplement for Sector Healthcare Value Fund was issued on 12 December 2014.

A revised Prospectus for Sector Capital Funds was issued on 12 December 2014.

### 19. Comparative period

The prior period comparatives are for the period 1 January 2013 to 31 December 2013.

Annual Report and Audited Financial Statements For the year ended 31 December 2014

# NOTES TO THE FINANCIAL STATEMENTS (Continued)

# 20. Significant events during the year

As disclosed in note 1 the Company launched the Sector Global Equity Kernel Fund on 19 March 2014.

There were no other significant events during the year.

# 21. Significant events after the balance sheet date

A revised Supplement for Sector Sigma Nordic Fund was issued on 20 March 2015 to include Class D Shares.

There were no other significant events after the balance sheet date.

# 22. Approval of Financial Statements

The financial statements were authorised for issue by the Directors on 16 April 2015.

**Annual Report and Audited Financial Statements** For the year ended 31 December 2014

# **SIGNIFICANT PORTFOLIO MOVEMENTS (Unaudited)**

In accordance with the European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations 2011, a statement of the largest changes in the composition of the Schedule of Investments during the year is provided to ensure that the shareholders can identify changes in the investments held by the Fund. These statements present the aggregate purchases and sales of an investment, exceeding 1% of the total value of purchases and sales for the year. At a minimum the largest 20 purchases and sales are listed. If the Fund enters into less than 20 purchases or sales during the year, then all transactions are presented.

# **Sector Global Equity Kernel Fund**

LADGEGE DUDGUAGEG	COST
LARGEST PURCHASES	COST USD
iShares MSCI ACWI Index Fund	1,373,574
Cal-Maine Foods, Inc.	209,580
Exxon Mobil Corp.	198,452
Westar Energy, Inc.	197,798
Cardinal Health, Inc.	191,602
Lintec Corp.	186,705
Ingredion Inc.	185,038
Berkeley Group Holdings PLC	180,033
Sonoco Products Co.	150,800
Hill-Rom Holdings, Inc.	148,676
Endesa S.A.	130,127
Maruichi Steel Tube Ltd.	119,578
CF Industries Holdings, Inc.	117,108
Ain Pharmaciez, Inc.	117,076
Freenet AG	116,737
IG Group Holdings PLC	116,314
Aaron's Inc.	115,286
CenturyLink, Inc.	114,637
Unum Group	114,237
Annaly Capital Management, Inc.	114,065
LARGEST SALES	PROCEEDS
	USD
iShares MSCI ACWI Index Fund	USD 1,366,786
iShares MSCI ACWI Index Fund The Cato Corp.	<b>USD</b> 1,366,786 131,630
iShares MSCI ACWI Index Fund The Cato Corp. Omnivision Technologies, Inc.	USD 1,366,786 131,630 125,376
iShares MSCI ACWI Index Fund The Cato Corp. Omnivision Technologies, Inc. CF Industries Holdings, Inc.	USD 1,366,786 131,630 125,376 121,296
iShares MSCI ACWI Index Fund The Cato Corp. Omnivision Technologies, Inc. CF Industries Holdings, Inc. Novartis AG	USD 1,366,786 131,630 125,376 121,296 120,063
iShares MSCI ACWI Index Fund The Cato Corp. Omnivision Technologies, Inc. CF Industries Holdings, Inc. Novartis AG Boiron S.A.	USD 1,366,786 131,630 125,376 121,296 120,063 116,675
iShares MSCI ACWI Index Fund The Cato Corp. Omnivision Technologies, Inc. CF Industries Holdings, Inc. Novartis AG Boiron S.A. Mitsubishi Tanabe Pharma Corp.	USD 1,366,786 131,630 125,376 121,296 120,063 116,675 114,649
iShares MSCI ACWI Index Fund The Cato Corp. Omnivision Technologies, Inc. CF Industries Holdings, Inc. Novartis AG Boiron S.A. Mitsubishi Tanabe Pharma Corp. Montpelier Re Holdings Ltd.	USD 1,366,786 131,630 125,376 121,296 120,063 116,675 114,649 113,816
iShares MSCI ACWI Index Fund The Cato Corp. Omnivision Technologies, Inc. CF Industries Holdings, Inc. Novartis AG Boiron S.A. Mitsubishi Tanabe Pharma Corp. Montpelier Re Holdings Ltd. The JM Smucker Co.	USD 1,366,786 131,630 125,376 121,296 120,063 116,675 114,649 113,816 113,185
iShares MSCI ACWI Index Fund The Cato Corp. Omnivision Technologies, Inc. CF Industries Holdings, Inc. Novartis AG Boiron S.A. Mitsubishi Tanabe Pharma Corp. Montpelier Re Holdings Ltd. The JM Smucker Co. AT&T, Inc.	USD 1,366,786 131,630 125,376 121,296 120,063 116,675 114,649 113,816 113,185 112,974
iShares MSCI ACWI Index Fund The Cato Corp. Omnivision Technologies, Inc. CF Industries Holdings, Inc. Novartis AG Boiron S.A. Mitsubishi Tanabe Pharma Corp. Montpelier Re Holdings Ltd. The JM Smucker Co. AT&T, Inc. Cal-Maine Foods, Inc.	USD 1,366,786 131,630 125,376 121,296 120,063 116,675 114,649 113,816 113,185 112,974 110,412
iShares MSCI ACWI Index Fund The Cato Corp. Omnivision Technologies, Inc. CF Industries Holdings, Inc. Novartis AG Boiron S.A. Mitsubishi Tanabe Pharma Corp. Montpelier Re Holdings Ltd. The JM Smucker Co. AT&T, Inc. Cal-Maine Foods, Inc. Unum Group	USD 1,366,786 131,630 125,376 121,296 120,063 116,675 114,649 113,816 113,185 112,974 110,412 110,140
iShares MSCI ACWI Index Fund The Cato Corp. Omnivision Technologies, Inc. CF Industries Holdings, Inc. Novartis AG Boiron S.A. Mitsubishi Tanabe Pharma Corp. Montpelier Re Holdings Ltd. The JM Smucker Co. AT&T, Inc. Cal-Maine Foods, Inc. Unum Group Leroy Seafood Group ASA	USD 1,366,786 131,630 125,376 121,296 120,063 116,675 114,649 113,816 113,185 112,974 110,412 110,140 108,904
iShares MSCI ACWI Index Fund The Cato Corp. Omnivision Technologies, Inc. CF Industries Holdings, Inc. Novartis AG Boiron S.A. Mitsubishi Tanabe Pharma Corp. Montpelier Re Holdings Ltd. The JM Smucker Co. AT&T, Inc. Cal-Maine Foods, Inc. Unum Group Leroy Seafood Group ASA Myriad Genetics, Inc.	USD 1,366,786 131,630 125,376 121,296 120,063 116,675 114,649 113,816 113,185 112,974 110,412 110,140 108,904 108,338
iShares MSCI ACWI Index Fund The Cato Corp. Omnivision Technologies, Inc. CF Industries Holdings, Inc. Novartis AG Boiron S.A. Mitsubishi Tanabe Pharma Corp. Montpelier Re Holdings Ltd. The JM Smucker Co. AT&T, Inc. Cal-Maine Foods, Inc. Unum Group Leroy Seafood Group ASA	USD 1,366,786 131,630 125,376 121,296 120,063 116,675 114,649 113,816 113,185 112,974 110,412 110,140 108,904
iShares MSCI ACWI Index Fund The Cato Corp. Omnivision Technologies, Inc. CF Industries Holdings, Inc. Novartis AG Boiron S.A. Mitsubishi Tanabe Pharma Corp. Montpelier Re Holdings Ltd. The JM Smucker Co. AT&T, Inc. Cal-Maine Foods, Inc. Unum Group Leroy Seafood Group ASA Myriad Genetics, Inc. Canon Marketing Japan, Inc. Mochida Pharmaceutical Co. Ltd.	USD 1,366,786 131,630 125,376 121,296 120,063 116,675 114,649 113,816 113,185 112,974 110,412 110,140 108,904 108,338 106,150
iShares MSCI ACWI Index Fund The Cato Corp. Omnivision Technologies, Inc. CF Industries Holdings, Inc. Novartis AG Boiron S.A. Mitsubishi Tanabe Pharma Corp. Montpelier Re Holdings Ltd. The JM Smucker Co. AT&T, Inc. Cal-Maine Foods, Inc. Unum Group Leroy Seafood Group ASA Myriad Genetics, Inc. Canon Marketing Japan, Inc.	USD 1,366,786 131,630 125,376 121,296 120,063 116,675 114,649 113,816 113,185 112,974 110,412 110,140 108,904 108,338 106,150 104,225
iShares MSCI ACWI Index Fund The Cato Corp. Omnivision Technologies, Inc. CF Industries Holdings, Inc. Novartis AG Boiron S.A. Mitsubishi Tanabe Pharma Corp. Montpelier Re Holdings Ltd. The JM Smucker Co. AT&T, Inc. Cal-Maine Foods, Inc. Unum Group Leroy Seafood Group ASA Myriad Genetics, Inc. Canon Marketing Japan, Inc. Mochida Pharmaceutical Co. Ltd. Eli Lilly & Co.	USD 1,366,786 131,630 125,376 121,296 120,063 116,675 114,649 113,816 113,185 112,974 110,412 110,140 108,904 108,338 106,150 104,225 103,641
iShares MSCI ACWI Index Fund The Cato Corp. Omnivision Technologies, Inc. CF Industries Holdings, Inc. Novartis AG Boiron S.A. Mitsubishi Tanabe Pharma Corp. Montpelier Re Holdings Ltd. The JM Smucker Co. AT&T, Inc. Cal-Maine Foods, Inc. Unum Group Leroy Seafood Group ASA Myriad Genetics, Inc. Canon Marketing Japan, Inc. Mochida Pharmaceutical Co. Ltd. Eli Lilly & Co. Kemper Corp.	USD 1,366,786 131,630 125,376 121,296 120,063 116,675 114,649 113,816 113,185 112,974 110,412 110,140 108,904 108,338 106,150 104,225 103,641 102,463

Annual Report and Audited Financial Statements For the year ended 31 December 2014

# SIGNIFICANT PORTFOLIO MOVEMENTS (Unaudited) (Continued)

# **Sector Healthcare Value Fund**

Abbvie, Inc.       USD         Baxter International, Inc.       5,038,876         Baxter International, Inc.       2,521,038         Sanofi-Aventis S.A.       2,462,272         Bristol-Myers Squibb Co.       2,273,617         Stryker Corp.       2,082,488         Hospira, Inc.       2,040,363         Boston Scientific Corp.       1,527,469         Otsuka Holdings Co. Ltd.       1,506,763         Edwards Lifesciences Corp.       1,308,141         Acorda Therapeutics, Inc.       1,180,365         Rite Aid Corp.       1,135,748         GlaxoSmithKline PLC       1,133,233         WellCare Health Plans, Inc.       1,072,721         Vertex Pharmaceuticals, Inc.       1,078,987         Thoratec Corp.       1,072,721         Bayer AG       1,068,903         AstraZeneca PLC       1,030,732         Mylan, Inc.       976,095         Eli Lilly & Co.       949,492
Baxter International, Inc.       2,521,038         Sanofi-Aventis S.A.       2,462,272         Bristol-Myers Squibb Co.       2,273,617         Stryker Corp.       2,082,488         Hospira, Inc.       2,040,363         Boston Scientific Corp.       1,527,469         Otsuka Holdings Co. Ltd.       1,506,763         Edwards Lifesciences Corp.       1,308,141         Acorda Therapeutics, Inc.       1,180,365         Rite Aid Corp.       1,135,748         GlaxoSmithKline PLC       1,33,233         WellCare Health Plans, Inc.       1,088,351         Vertex Pharmaceuticals, Inc.       1,072,721         Bayer AG       1,068,903         AstraZeneca PLC       1,030,732         Mylan, Inc.       976,095
Sanofi-Aventis S.A.       2,462,272         Bristol-Myers Squibb Co.       2,273,617         Stryker Corp.       2,082,488         Hospira, Inc.       2,040,363         Boston Scientific Corp.       1,527,469         Otsuka Holdings Co. Ltd.       1,506,763         Edwards Lifesciences Corp.       1,308,141         Acorda Therapeutics, Inc.       1,180,365         Rite Aid Corp.       1,135,748         GlaxoSmithKline PLC       1,332,33         WellCare Health Plans, Inc.       1,088,351         Vertex Pharmaceuticals, Inc.       1,072,721         Bayer AG       1,068,903         AstraZeneca PLC       1,030,732         Mylan, Inc.       976,095
Bristol-Myers Squibb Co.       2,273,617         Stryker Corp.       2,082,488         Hospira, Inc.       2,040,363         Boston Scientific Corp.       1,527,469         Otsuka Holdings Co. Ltd.       1,506,763         Edwards Lifesciences Corp.       1,308,141         Acorda Therapeutics, Inc.       1,180,365         Rite Aid Corp.       1,135,748         GlaxoSmithKline PLC       1,133,233         WellCare Health Plans, Inc.       1,088,351         Vertex Pharmaceuticals, Inc.       1,072,721         Bayer AG       1,068,903         AstraZeneca PLC       1,030,732         Mylan, Inc.       976,095
Stryker Corp.       2,082,488         Hospira, Inc.       2,040,363         Boston Scientific Corp.       1,527,469         Otsuka Holdings Co. Ltd.       1,506,763         Edwards Lifesciences Corp.       1,308,141         Acorda Therapeutics, Inc.       1,180,365         Rite Aid Corp.       1,135,748         GlaxoSmithKline PLC       1,133,233         WellCare Health Plans, Inc.       1,088,351         Vertex Pharmaceuticals, Inc.       1,072,721         Bayer AG       1,068,903         AstraZeneca PLC       1,030,732         Mylan, Inc.       976,095
Hospira, Inc.       2,040,363         Boston Scientific Corp.       1,527,469         Otsuka Holdings Co. Ltd.       1,506,763         Edwards Lifesciences Corp.       1,308,141         Acorda Therapeutics, Inc.       1,180,365         Rite Aid Corp.       1,135,748         GlaxoSmithKline PLC       1,133,233         WellCare Health Plans, Inc.       1,088,351         Vertex Pharmaceuticals, Inc.       1,072,721         Bayer AG       1,068,903         AstraZeneca PLC       1,030,732         Mylan, Inc.       976,095
Boston Scientific Corp.       1,527,469         Otsuka Holdings Co. Ltd.       1,506,763         Edwards Lifesciences Corp.       1,308,141         Acorda Therapeutics, Inc.       1,180,365         Rite Aid Corp.       1,135,748         GlaxoSmithKline PLC       1,133,233         WellCare Health Plans, Inc.       1,088,351         Vertex Pharmaceuticals, Inc.       1,072,721         Bayer AG       1,068,903         AstraZeneca PLC       1,030,732         Mylan, Inc.       976,095
Otsuka Holdings Co. Ltd.       1,506,763         Edwards Lifesciences Corp.       1,308,141         Acorda Therapeutics, Inc.       1,180,365         Rite Aid Corp.       1,135,748         GlaxoSmithKline PLC       1,133,233         WellCare Health Plans, Inc.       1,088,351         Vertex Pharmaceuticals, Inc.       1,072,721         Bayer AG       1,068,903         AstraZeneca PLC       1,030,732         Mylan, Inc.       976,095
Edwards Lifesciences Corp.       1,308,141         Acorda Therapeutics, Inc.       1,180,365         Rite Aid Corp.       1,135,748         GlaxoSmithKline PLC       1,133,233         WellCare Health Plans, Inc.       1,088,351         Vertex Pharmaceuticals, Inc.       1,078,987         Thoratec Corp.       1,072,721         Bayer AG       1,068,903         AstraZeneca PLC       1,030,732         Mylan, Inc.       976,095
Acorda Therapeutics, Inc.       1,180,365         Rite Aid Corp.       1,135,748         GlaxoSmithKline PLC       1,133,233         WellCare Health Plans, Inc.       1,088,351         Vertex Pharmaceuticals, Inc.       1,078,987         Thoratec Corp.       1,072,721         Bayer AG       1,068,903         AstraZeneca PLC       1,030,732         Mylan, Inc.       976,095
Rite Aid Corp.       1,135,748         GlaxoSmithKline PLC       1,133,233         WellCare Health Plans, Inc.       1,088,351         Vertex Pharmaceuticals, Inc.       1,078,987         Thoratec Corp.       1,072,721         Bayer AG       1,068,903         AstraZeneca PLC       1,030,732         Mylan, Inc.       976,095
GlaxoSmithKline PLC       1,133,233         WellCare Health Plans, Inc.       1,088,351         Vertex Pharmaceuticals, Inc.       1,078,987         Thoratec Corp.       1,072,721         Bayer AG       1,068,903         AstraZeneca PLC       1,030,732         Mylan, Inc.       976,095
WellCare Health Plans, Inc.       1,088,351         Vertex Pharmaceuticals, Inc.       1,078,987         Thoratec Corp.       1,072,721         Bayer AG       1,068,903         AstraZeneca PLC       1,030,732         Mylan, Inc.       976,095
Vertex Pharmaceuticals, Inc.       1,078,987         Thoratec Corp.       1,072,721         Bayer AG       1,068,903         AstraZeneca PLC       1,030,732         Mylan, Inc.       976,095
Thoratec Corp.       1,072,721         Bayer AG       1,068,903         AstraZeneca PLC       1,030,732         Mylan, Inc.       976,095
Bayer AG       1,068,903         AstraZeneca PLC       1,030,732         Mylan, Inc.       976,095
AstraZeneca PLC 1,030,732 Mylan, Inc. 1,030,732
Mylan, Inc. 976,095
Fli Lilly & Co 949 492
En Emy & 60.
AVANIR Pharmaceuticals, Inc. 926,886
Koninklijke Philips Electronics NV 874,968
Quest Diagnostics, Inc. 866,614
Takeda Pharmaceutical Co. Ltd. 856,532
Cigna Corp. 837,756
Dr Reddy's Laboratories Ltd. 836,244
Patterson Cos., Inc. 826,571
Community Health Systems, Inc. 801,947
Waters Corp. 767,335
Getinge AB 758,048
Smith & Nephew PLC 736,180
Teva Pharmaceutical Industries Ltd. 734,612
Shionogi & Co. Ltd. 729,372
Masimo Corp. 695,840
AmerisourceBergen Corp. 680,499
Ironwood Pharmaceuticals, Inc. 636,256
Basilea Pharmaceutica AG 592,380

Annual Report and Audited Financial Statements For the year ended 31 December 2014

# **SIGNIFICANT PORTFOLIO MOVEMENTS (Unaudited) (Continued)**

# Sector Healthcare Value Fund (continued)

LARGEST SALES	PROCEEDS
	USD
Abbvie, Inc.	5,509,677
Forest Laboratories, Inc.	5,016,957
Johnson & Johnson	4,495,184
Eli Lilly & Co.	3,849,975
Edwards Lifesciences Corp.	3,077,654
UnitedHealth Group, Inc.	2,618,442
Teva Pharmaceutical Industries Ltd.	2,497,389
Boston Scientific Corp.	2,476,692
Sanofi-Aventis S.A.	2,418,961
Baxter International, Inc.	2,387,507
AstraZeneca PLC	2,381,783
Smith & Nephew PLC	2,303,948
Cubist Pharmaceuticals, Inc.	2,241,162
AVANIR Pharmaceuticals, Inc.	2,177,495
Mallinckrodt PLC	2,160,956
Nobel Biocare Holding AG	2,025,042
Astellas Pharmaceutical Co. Ltd.	1,969,531
Acorda Therapeutics, Inc.	1,891,070
Meda AB	1,799,876
Bayer AG	1,713,154
Agilent Technologies, Inc.	1,636,350
ResMed, Inc.	1,604,084
Auxilium Pharmaceuticals, Inc.	1,533,346
Quest Diagnostics, Inc.	1,376,507
Volcano Corp.	1,336,782
Shionogi & Co. Ltd.	1,257,573
Allergan, Inc.	1,148,009
Thoratec Corp.	1,105,570
WellCare Health Plans, Inc.	1,090,581
Ironwood Pharmaceuticals, Inc.	965,291
Dr Reddy's Laboratories Ltd.	956,327
Cardinal Health, Inc.	925,956
Hospira, Inc.	874,662
Stada Arzneimittel AG	849,256
Vertex Pharmaceuticals, Inc.	849,240

Annual Report and Audited Financial Statements For the year ended 31 December 2014

# **SIGNIFICANT PORTFOLIO MOVEMENTS (Unaudited) (Continued)**

# Sector Sigma Nordic Fund

LARGEST PURCHASES	COST
	NOK
Yara International ASA	14,729,053
Investor AB	14,169,751
Petroleum Geo-Services ASA	12,571,675
BW LPG Ltd.	12,088,184
Novo Nordisk A/S	11,648,204
Trelleborg AB, Class B	10,559,886
Salmar ASA	10,375,184
Volvo AB	10,112,265
Skandinaviska Enskilda Banken AB	9,995,035
Baker Hughes, Inc.	9,388,664
Norsk Hydro ASA	8,860,175
Det Norske Oljeselskap ASA	8,813,408
Marine Harvest ASA	8,169,977
Tomra Systems ASA	7,756,527
AstraZeneca PLC	7,747,016
Telenor ASA	7,686,805
Cermaq ASA	7,619,877
Topdanmark A/S	7,437,340
Swedbank AB	7,433,285
SKF AB	7,309,439
Hexagon AB	7,304,711
Amer Sports Oyj	7,195,811
Millicom International Cellular S.A.	7,125,281
Svenska Cellulosa AB	7,098,781
Total S.A.	6,809,623
Seadrill Ltd.	6,505,286
Boliden AB	6,463,506
DSV A/S	6,411,920
Autoliy, Inc.	6,395,402
Exxon Mobil Corp.	6,390,018
Novozymes A/S	6,243,976
Outotec Oyj	6,186,584
RPC, Inc.	6,114,725
Assa Abloy AB	5,681,956
Aurora LPG Holding AS	5,630,992
Stolt-Nielsen Ltd.	5,535,421
Huhtamaki Oyj	5,047,529
Hexpol AB	4,647,607
ABB Ltd.	4,032,309
Opera Software ASA	3,289,933
-	

Annual Report and Audited Financial Statements For the year ended 31 December 2014

# **SIGNIFICANT PORTFOLIO MOVEMENTS (Unaudited) (Continued)**

# Sector Sigma Nordic Fund (continued)

LARGEST SALES	PROCEEDS
	NOK
Norsk Hydro ASA	19,497,218
Volvo AB	16,141,832
Trelleborg AB	14,824,712
Novo Nordisk A/S	14,268,434
Petroleum Geo-Services ASA	12,028,755
Novozymes A/S	11,897,440
Autoliv, Inc.	11,877,254
BW LPG Ltd.	11,678,261
ABB Ltd.	11,677,858
Royal Caribbean Cruises Ltd.	10,931,942
Cermaq ASA	10,722,949
Nordea Bank AB	10,149,969
Baker Hughes, Inc.	9,700,769
AstraZeneca PLC	9,053,733
SKF AB	8,200,091
Yara International ASA	6,917,950
Investor AB	6,713,486
Svenska Cellulosa AB	6,614,043
RPC, Inc.	6,589,447
Betsson AB	6,583,972
Konecranes Oyj	6,554,914
Seadrill Ltd.	6,549,965
Millicom International Cellular S.A.	6,441,421
Rockwool International A/S	6,431,237
Total S.A.	6,365,868
Exxon Mobil Corp.	6,363,830
Boliden AB	6,196,596
DSV A/S	6,195,795
Det Norske Oljeselskap ASA	6,104,388
Marine Harvest ASA	6,074,017
Bakkafrost P/F	5,640,600
Salmar ASA	5,637,139
Outotec Oyj	5,415,740
Stolt-Nielsen Ltd.	5,007,020
Meda AB	4,792,584
Stora Enso Oyj	4,672,520
Navios Maritime Acq Corp.	4,439,195
Statoil ASA	4,176,668
Huhtamaki Oyj	3,380,822